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Management of an ovarian tumour is a common problem faced by gynaecologists. The discri-
minative preoperative evaluation of ovarian tumours is rather difficult, as most ovarian masses 
are not immediately classifiable. The presumed diagnosis based on preoperative evaluation will 
guide the decision-making on the surgical approach. On the one hand, an incorrect preoperative 
diagnosis of benign disease may cause problems in the management of women with unexpected 
ovarian cancer, because their prognosis is influenced by appropriate surgery by a gynaecologic 
oncologist. On the other hand, incorrect preoperative diagnosis of malignancy may result in unne-
cessary anxiety and unnecessary referral to an oncology centre. The studies in this thesis evaluate 
opportunities to improve the preoperative and intraoperative diagnosis of ovarian tumours. 
BENIGN OVARIAN TUMOURS
Most ovarian tumours are benign, especially in women of reproductive age. Many are functional 
cysts that are harmless and resolve spontaneously. An ovarian cyst is a (mostly) fluid-filled sac 
that forms in the ovary. Ovarian cysts vary in size and may occur at different sites in the ovary: the 
most common type develops when an egg-producing follicle does not rupture and release the 
egg, but instead swells with fluid and forms a follicular cyst. Other types of benign cysts are der- 
moid cysts, cystadenomas and endometriomas. Benign ovarian tumours are usually slow-growing. 
Although benign ovarian tumours can probably be safely left in situ, treatment is often surgical. 
BORDERLINE OVARIAN TUMOURS
Borderline ovarian tumours, or ovarian cancers of low malignant potential, are classified 
between benign and malignant tumours as distinct entities. They differ from ovarian cancers by 
the absence of stromal invasion. They make up 15% to 20% of all epithelial ovarian tumours. 
Borderline ovarian tumours are primarily diagnosed in young women, are often found at an early 
stage, and have a high overall 5-year survival rate of up to 95%.1 Standard surgical treatment 
is staging surgery, which includes bilateral salpingo-oophorectomy and peritoneal staging 
procedures without lymph node sampling. In young women with early stage borderline ovarian 
tumours fertility-preserving staging, leaving the uterus and at least a part of one ovary in situ, is 
sufficient. 
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MALIGNANT OVARIAN TUMOURS
Ovarian cancer is the fourth most common cause of cancer-related death in women and has the 
worst prognosis of all gynaecological cancers. According to the data of the Dutch Association of 
Comprehensive Cancer Centres (ACCC), in the Netherlands in 2013, ovarian cancer was diagnosed 
in 1259 women, and 1010 women died from this disease.2 The majority of the malignant ovarian 
tumours are epithelial ovarian cancers, accounting for more than 90% of all ovarian malignancies. 
Epithelial ovarian cancers are subdivided in serous, mucinous, endometrioid, clear cell, and 
undifferentiated adenocarcinomas.3
Ovarian cancer confined to the ovary (International Federation of Gynecology and Obstetrics 
[FIGO] stage I disease) has a 5-year survival of 92%.4 However, detection of ovarian cancer at 
an early stage is difficult as ovarian cancer mostly remains asymptomatic in the earlier stages. 
Furthermore, the identity of a precursor lesion and how it develops into ovarian cancer is still not 
clear. No screening method has yet been proven to significantly affect mortality, even in a high-
risk population.5 Consequently, approximately 70% of the patients is diagnosed at an advanced 
stage of disease (FIGO IIB-IV). At that stage, the ‘silent lady killer’ has already spread throughout 
the abdomen and 5-year survival rates are poor.4 
The treatment of women with ovarian cancer depends on the stage of the disease. Optimal 
staging is necessary to determine which patients need adjuvant treatment, as only low-risk 
patients are treated with just surgery. According to the Dutch ACCC, optimal staging means: 
inspection and palpation of all serous surfaces in the abdominal cavity; aspiration of ascites or 
peritoneal washings for cytology; hysterectomy with bilateral salpingo-oophorectomy; infracolic 
omentectomy, and biopsies of: all locations to which the ovarian tumour has adhered to or grown 
into; all macroscopic locations and adhesions that are suspect; peritoneum of the pouch of 
Douglas; bladder peritoneum; peritoneum of the pelvic walls; left and right paracolic gutters; and 
the right diaphragm. Lymph node sampling should consist of resection of at least ten nodes, with 
lymph nodes sampled from the paraaortic and paracaval region, around the common, internal 
and external iliac vessels on both sides and from the obturator fossa. In case of a sub-optimal 
surgical staging, or in case of a poorly differentiated tumour, women with early stage ovarian 
cancer may benefit from adjuvant chemotherapy.6 
Treatment of women with advanced stage ovarian cancer consists of maximum cytoreductive 
surgery and platinum-based chemotherapy. The goal of primary cytoreductive surgery is to 
resect all macroscopic tumours and involves removal of the adnexa, uterus, and the infracolic 
part of the omentum. The amount of residual disease after primary cytoreductive surgery is an 
important predictor of prognosis.7,8 Ovarian cancer surgery is not part of the training programme 
of general gynaecologists. Studies have shown that survival rates of ovarian cancer patients are 
better when surgery is performed by a gynaecologic oncologist compared to surgery performed 
by general gynaecologists, leading to a 5- to 8-month median survival benefit for patients with 
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advanced stage disease. Furthermore, it has been shown that better debulking surgery results 
were obtained in high volume institutions.9-17
SPECIALISED CARE
In the Netherlands, the treatment of ovarian cancer was formally centralised from January 
2013 on. Before that, centralisation was already starting to develop. Different types of hospitals 
worked together within the framework of the eight comprehensive multi-hospital cancer 
centres. In the region of Nijmegen, the Radboud university medical center officially formed a 
regional collaboration with ten hospitals in the east of the Netherlands in the year 2000. The main 
goal of this collaboration was the improvement of care for gynaecological oncological patients, 
especially ovarian cancer patients. As part of this collaboration, gynaecologic oncologists at 
the centre hospital regularly assisted the gynaecologists in the community hospitals when 
performing surgery on patients with suspected ovarian cancer. The decision on when to operate 
in cooperation with a gynaecologic oncologist was difficult, despite improvements of imaging 
techniques and available tumour markers. A retrospective cohort study on all ovarian cancer 
patients in the Netherlands newly diagnosed between 1996 and 2003 showed that the majority 
of the ovarian cancer patients did not receive care in specialised settings.14,18 On the other hand, 
since the preoperative assessment of an adnexal mass is difficult, it was too often the case that 
gynaecologic oncologists were involved in surgery for benign ovarian cysts. 
PREOPERATIVE EVALUATION OF OVARIAN TUMOURS
Symptoms and physical examination
Most benign ovarian cysts do not cause symptoms. If present, the symptoms of benign ovarian 
cysts can include: mild abdominal pain; bloating or a feeling of fullness or pressure; dyspareunia; 
menstrual irregularities; sudden, sharp abdominal pain, fever and nausea in case of a torsion 
or rupture.
Borderline tumours and ovarian cancer in an early stage are usually asymptomatic as well. 
Physical findings are diverse and include the signs and symptoms that are also commonly 
caused by benign diseases. When these symptoms are caused by ovarian cancer, they tend to be 
persistent and represent a change from normal. Other symptoms of ovarian cancer can include: 
fatigue; indigestion; back pain; and constipation. However, these symptoms are aspecific and 
are also caused by other conditions, and occur just about as often in women who do not have 
ovarian cancer.19 When an ovarian mass is presented with ascites it is highly predictive of a 
borderline tumour or ovarian cancer. On the other hand, nearly half of borderline tumours and 
approximately 80% of early stage ovarian cancers do not produce ascites.20
11
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Imaging
If an ovarian tumour is suspected based on the patient history and physical examination, trans-
vaginal ultrasonography (TVS) is the most commonly employed imaging modality to further 
assess the pelvis. TVS allows for detailed imaging of the ovaries, determining their size and aspect, 
and the detection of morphological changes that may signify a malignancy. Ultrasonographic 
characteristics of malignancy are: multilocularity; septum thickness of more than 3 mm (no sharp 
boundary line); echo-dense areas; papillary masses in the cyst cavity; and ascites. Ultrasound 
images representative of benign and malignant pelvic tumours are shown in Figure 1.
Figure 1. (A) Benign tumour characterised by absence of solid components and absence of irregularities. 
(B) Malignant tumour characterised by presence of solid components and presence of irregularities.21
Experienced ultrasonographers in most cases are able to differentiate malignant from benign 
masses. The accuracy and the level of interobserver agreement both correlate with experience.22 
TVS is more sensitive than computed tomography (CT) scanning for the detection, assessment, 
and characterisation of pelvic masses.23,24 CT scan findings of complex functional cysts, benign 
ovarian tumours, and inflammatory and/or infectious masses can mimic ovarian malignancies. 
Magnetic resonance imaging (MRI) can also be used in the setting of a sonographically 
indeterminate adnexal mass. The presence of fat, haemorrhage, mucin, fluid, and solid tissue 
within an ovarian mass can be determined with the aid of MRI and is most useful in determining 
whether a mass is most likely benign.25 
A relatively new diagnostic tool in the assessment of an ovarian tumour is three-dimensional (3D) 
ultrasound. This technique visualizes the ovarian mass in all three planes (longitudinal, transverse 
and coronal), which offers the possibility of volume measurements and quantification of 
echogenicity of the ovarian tumour. A multicentre prospective study by Geomini et al.26 showed 
that the use of 3D ultrasound significantly improved the prediction of malignancy as compared to 
patient characteristics and 2D ultrasonography (areas under the receiver operator characteristic 
curve of 0.92 and 0.82, respectively, p=0.02), although the study included a relatively small sample 
size. Large prospective multicentre studies are needed to establish whether the improvement in 
diagnostic accuracy of the adnexal mass by the addition of 3D ultrasound is clinically relevant, 
especially since 3D ultrasound is currently not a standard tool in daily clinical practice. 
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Several authors27-30 have proposed the use of colour Doppler in those ovarian lesions that are 
difficult to classify, exhibit a complex appearance, or are suspicious for malignancy. The true 
diagnostic accuracy of this approach still needs to be determined.
Tumour markers
The serum tumour marker cancer antigen 125 (CA 125) level is widely used as a marker for 
a possible ovarian cancer in the primary assessment of an adnexal mass. In 80% of women 
with ovarian cancer, the CA 125 in serum is raised. This applies to a lesser degree to mucinous 
tumours and early stage disease. In women with early stage ovarian cancer, the CA 125 value 
in serum is only raised in 45% of the cases. CA 125 is not specific for ovarian cancer and may be 
elevated in a number of other malignancies, but also in benign ovarian tumours, menstruation, 
endometriosis, pregnancy, and pelvic inflammatory disease.31 It is therefore necessary to 
combine CA 125 with new tumour markers that provide better diagnostic efficiency. Recently, 
human epididymis protein 4 (HE4) has been proposed as a tumour marker for ovarian cancer.32,33 
Studies suggest that HE4 sensitivity and specificity in gynaecological diseases are better than 
with CA 125 and that both tumour markers are complementary. Moore et al.33 showed in their 
study that the combination of CA 125 and HE4 added 33.1% to the sensitivity of only CA 125 and 
3.5% to the sensitivity of only HE4. It needs to be further validated in order to decide if it should 
be recommended as a parameter for daily clinical decisions on patients with an ovarian mass. 
Besides conventional biomarkers, proteomic techniques offer a promising area of investigation. It 
regards cancer as a genetic disease, with genetic alterations leading to the production of abnormal 
proteins. Proteomic technology aids in the characterisation and validation of dysfunctional 
or altered proteins.34 An advantage is the ability to identify new potential biomarkers present 
in small amounts in the serum. Due to recent technologic advances in proteomics and also 
genomics, there have emerged many individual biomarkers that are currently being investigated 
for use.35,36
Prediction models
In spite of careful interpretations, the diagnostic procedures do not allow for establishing a 
definitive diagnosis of ovarian cancer preoperatively, but will only suggest its presence. Several 
efforts have been made to develop a practical and cost-effective method for the ovarian cancer 
risk estimation in patients with an adnexal mass. Table 1 presents an overview of externally 
validated prediction models.
13
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Table 1. Externally validated diagnostic models to estimate the risk of malignancy in adnexal masses.
 
Model
 
Type of model
 
Variables
Cut-off 
level
RMI-1 (Jacobs et 
al., 1990)
Scoring system (i) menopausal status, (ii) CA125, (iii) multilocular 
cysts, (iv) solid areas, (v) metastases, (vi) ascites, and 
(vii) bilaterality
200
RMI-2 (Tingulstad 
et al., 1996)
Scoring system same as RMI-1 200
RMI-3 (Tingulstad 
et al., 1999)
Scoring system same as RMI-1 200
RMI-4 (Yamamoto 
et al., 2009)
Scoring system same as RMI-1, with the addition of (vii) largest 
diameter of lesion
450
Tailor et al., 1997 Logistic 
regression
(i) papillations, (ii) age, and (iii) time averaged 
maximum velocity in tumour vessels
50%
Prömpeler et al., 
1997
Logistic 
regression
(i) ascites, (ii) solid lesion without shadowing, (iii) cyst 
with >30% solid part, (iv) diameter of the lesion, (v) 
multilocularity, and (vi) surface of the cyst
10%
Timmerman et al., 
1999
Logistic 
regression
(i) colour score, (ii) CA125, (iii) papillations, and (iv) 
menopausal status
25%
Timmerman et al., 
1999
Logistic 
regression
(i) papillations, (ii) irregular internal cyst wall, (iii) 
unilocular cyst, (iv) ascites, (v) bilaterality, (vi) 
menopausal status, and (vii) CA125
60%
Jokubkiene et al., 
2007
Logistic 
regression
(i) size of lesion (mean of 3 diameters), (ii) size of 
largest solid component (mean of 3 diameters), and 
(iii) any irregularity
12%
LR1 (Timmerman 
et al., 2005)
Logistic 
regression
(i) personal history of ovarian cancer, (ii) previous use 
of hormonal therapy, (iii) age, (iv) maximal diameter 
of the lesion, (v) pain, (vi) ascites, (vii) blood flow 
within papillary projection, (viii) solid tumour, (ix) 
maximal diameter of the largest solid component 
(bounded at 50 mm), (x) irregular internal cyst 
walls, (xi) acoustic shadows, and (xii) colour score of 
intratumoral blood flow
10%
LR2 (Timmerman 
et al., 2005)
Logistic 
regression
(i) age, (ii) ascites, (iii) blood flow within a solid 
papillary projection, (iv) maximal diameter of the 
largest solid component (bounded at 50 mm), (v) 
irregular internal cyst walls, and (vi) acoustic shadows
10%
Sassone et al., 1991 Morphologic 
score
(i) inner wall structure, (ii) wall thickness, (iii) septa, 
and (iv) echogenicity
9
Depriest et al., 
1993
Morphologic 
score
(i) tumour volume, (ii) wall structure, and (iii) septal 
structure
5
Lerner et al., 1994 Morphologic 
score
(i) wall structure, (ii) acoustic shadows, (iii) septa, and 
(iv) echogenicity
3
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Model
 
Type of model
 
Variables
Cut-off 
level
Ferrazzi et al., 1997 Morphologic 
score
(i) wall structure, (ii) septa, (iii) vegetation, and (iv) 
echogenicity
9
ANN1 (Timmerman 
et al., 1999)
Artificial neural 
network
(i) papillations, (ii) colour score, (iii) menopausal 
status, and (iv) CA125
45%
ANN2 
(Timmerman et al., 
1999)
Artificial neural 
network
(i) papillations, (ii) smooth surface, (iii) unilocularity, 
(iv) ascites, (v) bilaterality, (vi) menopausal status, and 
(vii) CA125
60%
Simple Rules 
(Timmerman et al., 
2008)
Ultrasound rules malignant criteria: irregular solid mass, colour 
score 4, irregular multilocular-solid mass ≥100 mm, 
ascites, at least 4 papillary structures; benign criteria: 
unilocular cyst, colour score 1, smooth multilocular 
tumour with largest diameter <100 mm, presence 
of acoustic shadows, presence of solid components 
where the largest solid component has a largest 
diameter <7 mm
n/a
ROMA (Moore et 
al., 2009)
Biomarker 
algorithm
(i) CA125, (ii) HE4, and (iii) menopausal status n/a
OVA-1 (Ueland et 
al., 2011)
Biomarker 
algorithm
(i) CA125, (ii) transferrin, (iii) transthyretin 
(prealbumin), (iv) apolipoprotein A1, and (vii) beta-2-
microglobulin
n/a
n/a, not applicable.
The Risk of Malignancy Index (RMI), introduced by Jacobs et al. in 1990,37 was the first prediction 
model suitable for use in clinical practice, and defines the optimal combination of diagnostic 
criteria. The RMI is the product of the ultrasound score (U), the menopausal score (M), and the 
absolute value of serum CA 125 level:
RMI = U x M x CA 125
The model for the original RMI was provided by a stepwise logistic regression analysis, which 
revealed that menopausal status, ultrasound score and serum CA 125 level were all significantly 
(p<.01) and independently related to the likelihood ratio for malignancy. The contribution of CA 
125 to the RMI was critical for assigning masses to the malignant category, whereas the main 
contribution of ultrasound was identifying benign disease. Menopausal status was, but age was 
not significantly related to the likelihood ratio, nor was any other interaction term significant. The 
exact formula for the likelihood ratio found was simplified in order to create the RMI, without loss 
of diagnostic precision. The likelihood ratio and logistic regression analysis were independent 
of the ratio of benign to malignant lesions in the studied population. The RMI can therefore be 
generalised to predict risk of malignancy in various populations. 
Table 1. Continued
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Five ultrasound features suggestive of malignancy make up the ultrasound score. These include 
the presence of multilocular lesions, solid areas, bilaterality, ascites, and intra-abdominal 
metastases. A U of zero was given when none of these features were present, a U of one was 
given if one of these features was detected, and a U of three was given if two or more of these 
features were detected. Premenopausal women were given an M of one and postmenopausal 
women were given an M of three. In cases with no ultrasound features suggestive of malignancy, 
the RMI becomes zero irrespective of the value of serum CA 125 level.
In 1996, Tingulstad et al.38 created their own model of RMI (RMI-2) by performing a stepwise forward 
logistic regression to re-establish independent predictors of malignancy. The best discrimination 
was found between the ultrasound score of two or more versus one or zero. Therefore, in the final 
model of RMI-2 the ultrasound variable was dichotomised into a comparison of ultrasound score 
zero or one as reference group (U=1) compared with that of two or more features (U=4). Similarly, 
an M of one was given to premenopausal women and an M of four to postmenopausal women. 
The main consequence of this modification of the RMI is that in cases with no ultrasound features 
suggestive of malignancy, the RMI could be over 200 in the presence of an elevated CA 125 level. 
Tingulstad et al. modified the RMI again in 1999 (RMI-3)39 by combining the ultrasound score of 
zero or one to give U=1, whereas for two or more features, U=3 was used in the equation. Also, M 
was given a value of one when premenopausal, and three when postmenopausal.
The three versions of the RMI have been validated retrospectively and prospectively in various 
clinical studies37-50 where a cut-off value of 200 showed the best discrimination between benign 
and malignant adnexal masses, with high sensitivity and specificity levels (sensitivity 51–90%, 
specificity 51–97%). A fourth RMI was introduced by Yamamoto et al. in 2009,51 which included 
tumour size as an additional parameter. The RMI is very popular because of its simplicity: little 
experience is needed to detect the ultrasound features that have to be scored. 
After the introduction of the tumour marker HE4, the Risk of Ovarian Malignancy Algorithm 
(ROMA) was developed, which is an algorithm that uses both CA 125 and HE4 along with 
menopausal status in a logistic regression model to classify patients with a pelvic mass into high-
risk or low-risk groups for having epithelial ovarian cancer.52-55 The main advantage of the ROMA 
algorithm is the sensitivity for the prediction of ovarian cancer in women with an ovarian tumour. 
A disadvantage of the ROMA is its relatively complex calculation method. More studies are 
necessary to clarify the best cut-off values for ROMA and to judge the validity of this instrument 
before its application in clinical practice. 
The International Ovarian Tumour Analysis (IOTA) models and rules (LR2 and Simple Rules) 
characterise adnexal tumours based upon the presence or absence of typical ultrasound features 
of malignancy (e.g. ascites, increased vascularisation, solid components, tumour size, papillary 
projections and irregular cyst walls).56,57 The most recent systematic review and meta-analysis 
evaluating the performance of prediction models and rules to characterise adnexal pathology 
16
Chapter 1
concluded that both LR2 and the Simple Rules perform better in differentiating the benign or 
malignant nature of an adnexal mass in a preoperative setting than any other included model.58
More recently, the IOTA group developed a new multiclass prediction model to preoperatively 
discriminate between benign, borderline, stage I invasive, stage II-IV invasive, and secondary 
metastatic ovarian tumours: the Assessment of Different Neoplasias in the adneXa (ADNEX) 
model.59 This model uses three clinical predictors (age, serum CA 125 level, type of centre) and six 
ultrasound predictors (maximal diameter of lesion, proportion of solid tissue, more than 10 cyst 
locules, number of papillary projections, acoustic shadows, and ascites). The first evaluation of 
the ADNEX model in an international multicentre prospective cohort study showed promising 
results.
To this day, no single prediction model has gained universal acceptance in routine daily practice. 
Ultimately, the optimal approach to characterizing ovarian masses remains the subjective 
interpretation of the ultrasound features of a mass by an experienced ultrasound examiner.22,60,61
INTRAOPERATIVE EVALUATION OF OVARIAN TUMOURS
An additional diagnostic procedure for the assessment of an adnexal mass is frozen section 
analysis during surgery. Frozen section analysis is widely used in the intraoperative evaluation of 
ovarian tumours and is generally accepted as a reliable method.62-64 It helps in making an informed 
decision on the extent of surgery, such as removal of the contralateral ovary, hysterectomy, or 
the necessity for staging, and therefore preventing both under- and overtreatment. The frozen 
section procedure includes the examination of one or two sections of the most suspicious parts 
of the removed tissue. The diagnosis may be expected within 20-30 minutes and is preferably 
limited to a “benign”, “borderline” or “malignant” diagnosis. The technical quality of the frozen 
section is lower compared to the formalin fixed, wax embedded tissue processing. 
The accuracy in diagnosing ovarian cancer has been assessed in previous studies. A systematic 
review by Geomini et al.62 showed high levels of sensitivity and specificity (71–100% and 98–
100%, respectively) for frozen section analysis. In contrast, frozen section analysis of borderline 
ovarian tumours appears to be less accurate. Tempfer et al.65 presented a pooled analysis of four 
studies that included 317 women with borderline ovarian tumours. The overall sensitivity was 71% 
and the positive predictive value was 84%. 
As a frozen section procedure only includes the examination of one or two sections of the most 
suspicious parts of the removed tissue in a limited time frame, frozen section analysis cannot be 
accurate in all cases. The comparison of all kind of tumours has shown that most misdiagnoses 
on frozen sections occur in mucinous ovarian tumours.62,64,66,67 Since mucinous ovarian tumours 
frequently contain benign, borderline, and malignant components at the same time and have 
17
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relatively larger dimensions, they are more likely to be underdiagnosed than serous tumours.68 
The most common problems in differential diagnosis include the distinction of borderline 
tumours from carcinomas, and the distinction of primary versus metastatic carcinoma. 
A report by Geomini et al.69 has shown that also tumour size has an effect on the accuracy of 
frozen section analysis. In masses with a diameter of 10 cm or larger, a benign result of the frozen 
section analysis was less reliable than in masses with a diameter of less than 10 cm. In women 
with masses of 10 cm or larger, 11% of the women in whom frozen section analysis indicated a 
benign cyst turned out to have a malignant or borderline tumour according to the final pathology. 
In women with a tumour smaller than 10 cm, only 2% of the women with a benign frozen section 
diagnosis had a false negative diagnosis. Additionally, some authors have reported retrospective 
studies in which they suggest that the accuracy of frozen section analysis improved when 
performed by an expert pathologist.70,71
Gynaecologists can decide prior to or during surgery whether frozen section analysis will be 
needed, and they may alter the decision during surgery, depending on the intraoperative 
findings. Various factors influence the surgeon’s use of frozen section analysis, depending on the 
suspicion of malignancy.72
LAPAROSCOPIC EVALUATION OF OVARIAN TUMOURS
Laparoscopy is a common approach for the surgical removal of (presumably benign) ovarian 
tumours. The decision whether or not to use a laparoscopic approach, is based on the clinical 
impression of the tumour or its size. Advantages of laparoscopic gynaecologic surgery over 
laparotomy are: significantly less postoperative pain, fewer adverse events of surgery (surgical 
injury or postoperative complications), better cosmetic results, and a shorter length of hospital 
stay.73 Laparoscopy is, however, associated with an increased rate of intraperitoneal spillage. In 
malignant tumours this may lead to dissemination of tumour cells, an upgrade in tumour stage, 
and subsequently a risk of adjuvant chemotherapy needed.74 An additional concern is the risk of 
laparoscopic port-site metastases.75 Nonetheless, a review of literature on the role of minimally 
invasive surgery in staging of ovarian cancer76 and a recent retrospective study77 have concluded 
that patients with borderline ovarian tumours and apparent early stage ovarian malignancies can 
safely and effectively undergo laparoscopic surgical management. The studies were conducted in 
oncology centres and surgeries were performed by trained gynaecologic oncologists.
No protocols have been introduced yet concerning the procedure and interpretation of ovarian 
tumours during surgery. A standardised examination of an ovarian tumour might improve the 
value and use of frozen section analysis. 
18
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AIMS AND OUTLINE OF THE THESIS
Accurate preoperative diagnosis in women with ovarian tumours is essential for optimal care. 
In case of doubt, frozen section analysis during surgery helps in making an informed decision 
in regard to the extent of surgery, preventing both under- and overtreatment. The aims of this 
thesis are to evaluate opportunities to improve the preoperative and intraoperative diagnosis of 
ovarian tumours. The objectives are as follows:
1. To verify the effectiveness of the Risk of Malignancy Index in daily clinical practice.
2. To validate an adapted Risk of Malignancy Index.
3. To evaluate the use of frozen section analysis in ovarian tumours.
4. To evaluate whether standardised laparoscopic examination of an ovarian tumour 
is feasible.
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ABSTRACT
Objective
To verify the effectiveness of the Risk of Malignancy Index (RMI) in the discrimination between 
non-invasive (benign and borderline) lesions and invasive malignant adnexal masses in daily 
clinical practice.
Methods
This prospective observational study was conducted in a multicentre cooperation of 11 hos-
pitals. A total of 548 women with adnexal masses were included. Ultrasound characteristics, 
menopausal status and serum CA 125 level were registered preoperatively, and combined into 
the RMI afterwards. Final diagnosis was based on routine histopathologic examination. The 
decision to have patients operated by or with a gynaecologic oncologist was based on the clinical 
impression of the gynaecologist in the local hospital, based on physical examination, testing of 
serum samples, and ultrasound examination. This was compared with the hypothetical situation 
in which the RMI would have been applied as method of selection.
Results
An RMI of 200 achieved a sensitivity of 81% and specificity of 85% in the detection of ovarian 
cancer. Positive and negative predictive values were 48% and 96% respectively. In current 
practice, 64% of ovarian cancer patients were operated by a gynaecologic oncologist. This 
percentage would have increased to 80% if the RMI with a cut-off value of 200 would have been 
used as method of selection.
Conclusions
In our study population, introduction of the RMI would improve the management of adnexal 
masses, with a higher percentage of ovarian cancer patients that are operated by a gynaecologic 
oncologist. At the same time, referral of patients with non-invasive (benign and borderline) 
lesions would be reduced.
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INTRODUCTION
Ovarian cancer is the leading cause of death from gynaecologic malignancies in The Netherlands. 
Most cases are diagnosed at advanced stage where prognosis is poor. Several studies have 
demonstrated that ovarian cancer patients operated by a gynaecologic oncologist are more 
likely to undergo accurate staging and optimal cytoreductive surgery compared to patients 
who are operated by general gynaecologists.1-10 To improve the quality of care, gynaecologic 
oncologists from academic centres operate in local hospitals on patients with adnexal masses 
suspect for malignancy in most Dutch regions, following a standardised treatment protocol. 
The Radboud University Nijmegen Medical Center (RUNMC) has formed such a multicentre 
cooperation with 10 hospitals in the east of the Netherlands. The decision on whether or not a 
gynaecologic oncologist needs to be called upon is currently based on the clinical impression of 
the gynaecologist at the local hospital. 
The discriminative preoperative evaluation of adnexal masses is rather complicated. A variety 
of diagnostic procedures is used, leading to a wide variety of variables which can result in an 
inaccurate interpretation of the nature of the adnexal mass. Efficiency of care for ovarian cancer 
patients can be improved by standardizing this preoperative evaluation. Jacobs et al.11 developed 
the Risk of Malignancy Index (RMI) for referral of relevant patients to gynaecologic oncologic 
centres. The RMI was the first diagnostic model that combined demographic, sonographic and 
biochemical data in the assessment of patients with adnexal masses. The main advantage of this 
method compared with other diagnostic procedures is that the RMI is a simple scoring system that 
can be applied directly into clinical practice without the introduction of expensive or complicated 
methods. The RMI has been adjusted by Tingulstad et al.12 in 1996 (RMI-2) and again in 1999 
(RMI-3).13 The three versions of the RMI have been validated retrospectively and prospectively in 
various clinical studies11-24 where a cut-off value of 200 showed the best discrimination between 
benign and malignant adnexal masses, with high sensitivity and specificity levels (sensitivity 51–
90%, specificity 51–97%). 
Two studies22,25 have included patients in a multicentre study. An important limitation of the 
study from Bailey et al.22 is that the study population consisted of patients who had already been 
referred to the oncologic centre for treatment of a potential ovarian cancer. In the International 
Ovarian Tumour Analysis Group (IOTA) study,25 a cut-off value of 100 was used, while 200 is 
commonly regarded as the most optimal cut-off level. Consequently, the effectiveness of the RMI 
in clinical application, acknowledging local variations in the serum CA 125 assay and ultrasound 
expertise, still needs to be assessed. 
The aim of the present study was to prospectively verify the effectiveness of the RMI versus 
clinical impression (of the gynaecologist in the local hospital) to discriminate between non-
invasive (benign and borderline) lesions and invasive malignant adnexal masses in daily clinical 
practice, allowing local variations in serum CA 125 assay and ultrasound expertise. 
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MATERIALS AND METHODS
This prospective observational study was conducted between January 2005 and January 2008 
in the RUNMC, an academic hospital, and 10 cooperating hospitals, all general hospitals, in the 
east of the Netherlands. Women with adnexal masses, due to be admitted for surgery, were 
included. Gynaecologists registered the individual parameters of the RMI and returned them 
on a registration form to the RUNMC. As proposed by Tingulstad et al.13 in 1999, RMI is defined 
as the multiplied value of the ultrasound score (U), menopausal status (M) and serum CA 125 
level: RMI=U×M×CA 125. Multilocularity, solid areas, bilaterality, ascites and intraabdominal 
metastases score one point each. A total of 2 or more points gives U=3, fewer than 2 points 
gives U=1. Postmenopausal status is defined as more than 1 year of amenorrhoea, or age 50 
years or older among women who had prior hysterectomies, and scores M=3; premenopausal 
status scores M=1. Serum CA 125 (U/mL) is entered directly into the equation. Ultrasound was 
performed by transvaginal examination and abdominal examination if needed. The ultrasounds 
were performed by gynaecologic oncologists, general gynaecologists, or gynaecology residents. 
Serum samples were analysed for CA 125 as part of routine preoperative assessment, and 
menopausal status was registered. Final diagnoses of included patients were based on the 
histopathologic examination of surgical specimens. Patients diagnosed with non-gynaecologic 
malignancies were excluded from the study. 
The derived RMI was merely registered and not applied in further planning of care. Based on 
the clinical impression by the gynaecologist in the local hospital it was decided if a gynaecologic 
oncologist would be involved in the surgical treatment. This clinical impression was based on 
the routine preoperative assessment, consisting of physical examination, testing of serum 
samples, and ultrasound examination. The local gynaecologists varied in levels of expertise, 
from gynaecologists specialising in oncology to gynaecology residents. It was agreed upon at 
the beginning of the study that the RMI result would not be used in further decision making. The 
effect of using the RMI could retrospectively be estimated by creating a hypothetical situation in 
which the RMI with a cut-off value of 200 would have been applied to decide whether or not an 
oncologist would be invited to perform the operation. This hypothetical situation was compared 
with daily clinical practice. 
Statistical analyses were performed using the Statistical Packages for the Social Sciences Version 
14.0.1 (SPSS Inc., Chicago, IL). Borderline malignancies were allocated to the non-invasive group 
in all analyses. Comparison between patients with non-invasive (benign and borderline) lesions 
and invasive malignancies was performed using the Mann–Whitney U test for age and serum CA 
125 level, the Pearson χ2 test for menopausal status and the Kruskal–Wallis test for ultrasound 
score. A receiver operating characteristic (ROC) curve was created to show the relation between 
sensitivity and specificity of the RMI in the discrimination between non-invasive lesions and 
invasive malignancies.
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RESULTS
A total of 548 patients were included in the study. A number of 415 patients (76%) were 
diagnosed with benign gynaecologic conditions, whereas 80 patients (14%) had malignant 
diseases. Borderline malignancies were diagnosed in 53 patients (10%). The distribution of age, 
menopausal status, ultrasound score and serum CA 125 level in the non-invasive and invasive 
groups is shown in Table 1. Statistically significant differences between the two groups were 
observed for all these variables. 
Table 1. Distribution of age, menopausal status, ultrasound score and serum CA 125 levels in 548 patients 
with non-invasive lesions (n=468) and invasive malignant (n=80) adnexal masses.
  
Characteristic
Non-invasive lesions
(n=468)
Invasive malignancies
(n=80)
Significance level 
(p)
Age (years)
Median (range) 52 (13-90) 62 (24-89) 0.000b
Postmenopausal
n (%) 254 (54) 60 (75) 0.001c
Ultrasound scorea
0 
n (%)
1
n (%)
2-5
n (%)
132 (28)
177 (38)
159 (34)
3 (4)
12 (15)
65 (81)
0.000d
Serum CA 125 (U/mL)
Median (range) 18 (2-1380) 180 (7-3214) 0.000b
a Ultrasounds were scored one point for each of the following characteristics: multilocularity, solid areas, 
bilaterality, ascites and intra-abdominal metastases.
b Mann-Whitney U test.
c Pearson χ2 test.
d Kruskal-Wallis test.
The final histopathologic diagnoses are listed in Table 2. The majority of non-invasive 
gynaecologic conditions included mucinous cystadenomas (n=93) and serous cystadenomas 
(n=69). Histopathologic diagnoses in invasive malignant diseases were mainly serous 
cystadenocarcinomas (n=32). In patients with non-invasive gynaecologic conditions the median 
RMI is 48, with values ranging from 4 to 12420. The median RMI in the invasive malignant group 
is 1063, with values ranging from 22 to 28926.
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Table 2. Distribution of histopathologic diagnoses.
n %
Non-invasive lesions (n=468)
Mucinous cystadenomas
Serous cystadenomas
Other cystadenomas
Simple cysts
Endometriotic cysts
Dermoids
Fibroma
Mucinous borderline
Serous borderline
Others
93
69
10
64
49
48
45
25
16
49
20
15
2
14
10
10
10
6
3
10
Invasive malignancies (n=80)
Serous cystadenocarcinomas
Mucinous cystadenocarcinomas
Endometrioid adenocarcinomas
Undifferentiated adenocarcinomas
Clear cell carcinomas
Carcinosarcomas
Granulosa cell tumors
Others
32
8
10
11
12
3
2
2
40
10
13
14
15
4
2
2
The diagnostic performance of the RMI is illustrated in Fig. 1. A cut-off level of 200 gives a 
sensitivity of 81% and a specificity of 85%. Positive and negative predictive values at that cut-off 
level are 48% and 96%, respectively. 
When comparing the performance of the RMI between premenopausal and postmenopausal 
patients, premenopausal patients show lower sensitivity (55%) and PPV values (29%) compared 
to postmenopausal patients (90% and 56% respectively) at a cut-off level of 200. The diagnostic 
performances of the RMI in these two groups is illustrated in Figs. 2 and 3, respectively.
A total of 70 patients with non-invasive gynaecologic conditions scored an RMI of 200 or more. 
These cases are considered false positive. The corresponding histopathologic diagnoses are 
listed in Table 3. A substantial number concerns fibromas (n=15) and endometriotic cysts (n=13). 
Conversely, 15 patients with invasive malignancies scored an RMI less than 200, and are con-
sidered false negative. Corresponding histopathologic diagnoses are also shown in Table 3. 
Clear cell carcinomas made up 40% of all false-negative cases (n=6). Fifty percent of all clear cell 
carcinomas which were found in the study had an RMI below 200 (n=6). Two patients presented
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Figure 1. The receiver operating characteristic 
(ROC) curve of the Risk of Malignancy Index (RMI) 
applied to the study population (n=548). The area 
under the curve is 0.893.
Figure 2. The receiver operating characteristic 
(ROC) curve of the Risk of Malignancy Index 
(RMI) in premenopausal patients (n=294). 
The area under the curve is 0.839.
Figure 3. The receiver operating characteristic 
(ROC) curve of the Risk of Malignancy Index (RMI) 
in postmenopausal patients (n=254). The area 
under the curve is 0.911.
with multilocularity and solid areas: one being postmenopausal with a CA 125 of 7 U/ml (RMI=63) 
and the other being premenopausal with a CA 125 of 56 U/ml (RMI=168). Three patients presented 
with only solid areas on ultrasound: two of them were postmenopausal with CA 125 levels of 
23 and 27 U/ml (RMI=69 and 81), the other was premenopausal with a CA 125 level of 22 U/ml 
(RMI=22). One premenopausal patient presented with only multilocularity on ultrasound and a 
CA 125 level of 69 (RMI=69). 
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Table 3. False-positive and false-negative cases with corresponding histopathologic diagnoses.
n %
False-positive cases (n=70)
Histopathologic diagnosis 
Endometriotic cysts 
Serous borderline
Mucinous borderline
Mucinous cystadenomas 
Other cystadenomas 
Fibroma 
Dermoids
Other 
13
8
7
7
6
15
4
10
19
11
10
10
9
21
6
14
False-negative cases (n=15)
Histopathologic diagnosis
Clear cell carcinomas 
Serous cystadenocarcinomas 
Mucinous cystadenocarcinomas 
Endometrioid adenocarcinomas
Other adenocarcinomas 
Mullerian adenosarcomas 
6
3
1
2
2
1
40
20
7
13
13
7
The cooperation between the RUNMC and local hospitals is currently based on the clinical 
impression of the gynaecologist in the local hospital. This current practice was compared with 
a hypothetical situation, in which the RMI with a cut-off level of 200 would have been applied to 
decide which patient would be operated by a gynaecologic oncologist. In this way, the effects 
of using the RMI in clinical practice can be predicted. In current practice, 64% of ovarian cancer 
patients were operated by a gynaecologic oncologist. This percentage would increase to 80% 
when the RMI with a cut-off value of 200 would have been used as method of selection. On the 
other hand, in current practice 56% of operations performed by oncologists concerned non-
invasive (benign or borderline) diseases. In the hypothetical situation, referral of these patients 
would be reduced to 50%.
DISCUSSION
The results of the present study confirm previous publications indicating that the RMI improves 
the discrimination between non-invasive (benign and borderline) and invasive malignant adnexal 
masses. The current study population consisted of patients who were preoperatively evaluated 
without the application of the RMI. Based on the individual clinical impression of the gynaecologist 
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at the local hospital it was decided if an oncologist from the academic centre was required to 
perform the operation. By using the registered information, the RMI was derived from the very 
same study population, to hypothesise how the situation would change when the RMI value 
was used to determine which patients should be operated by an oncologist. In this manner, the 
effects of actually applying the RMI can be estimated in a way that to our knowledge has not been 
published so far. We have thus compared the current practice with the hypothetical situation 
in which the RMI would have been applied to decide which patient should be operated by an 
oncologist. In current practice, 64% of ovarian cancer patients were operated by an oncologist. 
This would increase to 80% when the RMI would be used as method of selection. Most of the extra 
patients that would have been operated by a gynaecologic oncologist were early stage cases in 
which proper staging is of great importance. Still these results do not lead to the most optimal 
situation, because 20% of ovarian cancer patients would not have been operated in an optimal 
setting even with the introduction of the RMI. The fact that 40% of these “failures” consists of 
clear cell carcinomas makes this even more problematic. The ability of the RMI to detect different 
histological types of ovarian malignancies was tested by Aslam et al.16 in 2000. They found that 
the RMI performed best in diagnosing invasive epithelial cancer, with a sensitivity of 93%.
Future research on optimising the preoperative discrimination between non-invasive (benign 
and borderline) and invasive malignant adnexal masses by using new ultrasound techniques or 
better serum markers could further improve the quality of care. 
We acknowledge that an experienced ultrasound examiner can evaluate an adnexal mass with high 
accuracy by pattern recognition, as has been demonstrated by van Calster et al.26 They showed 
in their study that 752 (93%) of the 809 tumours were correctly classified as malignant or benign 
by pattern recognition. Recently, Yazbek et al.27 have demonstrated in a prospective randomised 
controlled study that the quality of gynaecological ultrasonography has a significant influence 
on the management of patients with suspected ovarian cancer. Experienced sonographers were 
particularly better in diagnosing benign adnexal pathology. This was based on the evaluation of 
150 patients who were already referred to the regional gynaecologic cancer centre. The study did 
not show how effective the initial referral of relevant patients to the cancer centre was, whereas 
our present study especially focused on this aspect. 
We have chosen to use the RMI as developed by Tingulstad et al.13 and not the first version as 
developed by Jacobs et al.11 The main reason for this is that Jacobs et al. gave an ultrasound score 
(U) of 0 when none of the ultrasound features were present, resulting in an RMI of 0 regardless 
of the CA 125 level. We consider the CA 125 level as an important parameter of the RMI and 
therefore decided to use the version as proposed by Tingulstad et al. Recently, Yamamoto et 
al.28 published their study in which a fourth RMI was created, that includes tumour size as an 
additional parameter. The RMI-4 was compared with the previous RMIs and showed improved 
performance at a cut-off level of 450. It concerns a retrospective study, the RMI-4 still needs to be 
validated prospectively in different institutions. 
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Like most previous studies, data from the present study indicate that an RMI of 200 gives the 
most optimal cut-off value when regarding the entire group of ovarian tumours. Some authors 
have suggested a different cut-off value.15,19,24 This is probably a result of a difference in population 
characteristics: the amount of exceptional and borderline tumours and especially the prevalence 
of malignancy. For it is well known that, for any test, the positive predictive value will be lower and 
the negative predictive value higher when used in populations where the disease is uncommon. In 
our study population, 14% of the patients were diagnosed with invasive malignancies. In hospitals 
that cover populations with higher prevalences of invasive malignancies, the RMI cut-off value 
might need to be adjusted. The proposed cut-off value may also be dependent on the region 
where the RMI is used. When the availability of gynaecologic oncologists is easily arranged, a 
lower RMI cut-off may be used, to aim for every invasive malignancy to always be operated on by 
an optimal team. However, when the availability of gynaecologic oncologists is limited, a higher 
RMI cut-off value may be more convenient. 
Borderline malignancies tend to have lower RMI-values compared to invasive malignancies 
and are therefore less detectable. This can be explained by the different features they exhibit, 
therefore they have low scores both on ultrasound and CA 125 level.29 One must keep in mind 
that the primary goal for developing the RMI is the referral of patients with invasive malignant 
diseases to gynaecologic oncologists. Some borderline malignancies with invasive implants do 
require significant gynaecological oncological debulking. The majority of patients with borderline 
malignancies however do not necessarily have to be operated by a gynaecologic oncologist 
to optimise their survival chances. Therefore, borderline malignancies were allocated to the 
non-invasive group when calculating the sensitivity and specificity levels, leaving only invasive 
malignancies to be detected for referral to a gynaecologic oncologist. 
A difference in performance of the RMI was detected when dividing the study population 
into a pre- and postmenopausal group. The RMI predicted invasive malignancy best in the 
postmenopausal group. The most important explanation is a different mix of histology in 
ovarian tumours occurring in pre- and postmenopausal patients, with a higher incidence of 
ovarian cancer in postmenopausal women. Ovarian enlargements and ovarian masses are 
furthermore more frequently detected in premenopause, due to e.g. the occurrence of ovulation 
disorders.30,31 Secondly, the diagnostic accuracy of serum CA 125 assay is expected to be lower in 
premenopausal patients. CA 125 levels fluctuate during the menstrual cycle, being the highest 
during menstruation. Also, diseases such as endometriosis and pelvic inflammatory disease are 
more frequent in premenopause. These diseases are known to cause elevated CA 125 values.30 
Indeed, our data show that endometriotic cysts make up a substantial amount of false positive 
cases, due to relatively high CA 125 levels. Although some young patients with endometriosis or 
other gynaecological conditions that increase the CA 125 level should not be denied the exposure 
to a gynaecologic oncologist, most benign diseases can be treated by a general gynaecologist. 
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All CA 125 assays and ultrasounds were performed at the local hospitals. Using different assays 
for CA 125 analysis reflects clinical practice. This was likewise the case for the ultrasounds which 
were performed by local gynaecologists. In other studies, the ultrasounds were performed by 
expert radiologists.11,14,16 This is preferable in the initial evaluation of a given test, to ensure its 
reproducibility. It is however the case that in clinical practice, ultrasounds are performed by a 
variety of gynaecologists with a different expertise. The present study was therefore carried out 
in the realistic setting of daily practice, not in a controlled study setting that differs from reality. 
In conclusion, data from the present study imply that using the RMI increases the percentage of 
ovarian cancer patients in whom surgery is performed by a gynaecologic oncologist. Moreover, 
using the RMI may lead to a decrease of the percentage of patients with non- invasive (benign and 
borderline) lesions where a gynaecologic oncologist was unnecessarily present at the operation. 
Further research is recommended to determine the actual effect of the use of the RMI in the 
clinical management of adnexal masses.
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ABSTRACT
Objective
The Risk of Malignancy Index (RMI) is a simple scoring system to standardize and improve the 
preoperative evaluation of adnexal masses. Since 1990, three versions of the RMI have been 
validated in various clinical studies. Recently, a fourth version of the RMI (RMI-4) was introduced 
that includes tumour size as an additional parameter. The aim of this study was to validate the 
ability of RMI-4 to discriminate between non-invasive lesions and invasive malignant adnexal 
masses, and to compare its performance with RMI-3.
Study design
Women scheduled for surgery for an adnexal mass between 2005 and 2009 in 11 hospitals were 
included. Ultrasonographic characteristics, menopausal status and serum CA 125 level were 
registered preoperatively, and combined into the RMI. The performances of RMI-3 and RMI-4 
were assessed and statistically tested for differences.
Result
A total of 643 patients were included: 469 benign, 73 borderline and 101 malignant tumours. The 
RMI-3 had a sensitivity of 76%, specificity of 82%, positive and negative predictive values (PPV 
and NPV) of 45% and 95%, and an accuracy of 81%. The RMI-4 had a sensitivity of 74%, specificity 
of 79%, PPV of 40%, NPV of 94%, and an accuracy of 78%. The accuracy of RMI-3 was significantly 
higher than the accuracy of RMI-4 (p =.001). Both models had an area under the curve of 0.86.
Conclusion
Both RMI-3 and RMI-4 were able to discriminate between non-invasive lesions and invasive 
malignant adnexal masses, with similar performances. Including tumour size in the RMI does not 
improve its performance.
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INTRODUCTION
The discriminative preoperative evaluation of adnexal masses is rather complicated. A variety 
of diagnostic procedures has been used, leading to a wide range of variables which can result in 
an inaccurate interpretation of the nature of the adnexal mass. In view of treatment of ovarian 
cysts, the assessment between benign and malignant needs to be performed as accurate as 
possible. To standardize and improve the preoperative evaluation, Jacobs et al.1 developed the 
Risk of Malignancy Index (RMI), which is a simplification of a formula found by logistic regression 
analysis. The RMI was the first diagnostic model that combined demographic, sonographic and 
biochemical data in the assessment of patients with adnexal masses. The main advantage of this 
method compared with other diagnostic models is that the RMI is a simple scoring system that 
can be applied directly into clinical practice without the introduction of expensive or difficult 
tools. The original RMI is known as RMI-1. The RMI has been modified by Tingulstad et al. in 1996 
(RMI-2)2 and again in 1999 (RMI-3).3 The difference between these three measurement tools lies 
in the different scoring of ultrasound characteristics and menopausal status. The three versions of 
the RMI have been validated retrospectively and prospectively in various clinical studies1-15 where 
a cut-off value of 200 showed the best discrimination between benign and malignant adnexal 
masses, with high sensitivity and specificity levels (sensitivity 51–90%, specificity 51–97%). 
Recently, a fourth RMI was introduced by Yamamoto et al.16 which includes tumour size as an 
additional parameter. They found that a cut-off level of 450 in RMI-4 is comparable with a cut-
off level of 200 in the three previous RMIs. When they compared the RMI-4 in a retrospective 
study with 253 cases with the previous RMIs, an improved performance at a cut-off level of 450 
was found, with an accuracy of 90%. The RMI-4 still needs to be validated prospectively and in 
different institutions, to assess external validity. The aim of the present study was to validate the 
ability of RMI-4 to discriminate between non-invasive lesions and invasive malignant adnexal 
masses in daily clinical practice, and to compare its performance with RMI-3.
MATERIALS AND METHODS
This study was conducted between January 2005 and September 2009 in the Radboud University 
Nijmegen Medical Center (RUNMC), a third line regional referral hospital, and in 10 cooperating 
hospitals in the east of the Netherlands. The study was approved by the medical ethics committee 
of the RUNMC. The study included 643 women admitted for surgical procedure for an adnexal 
mass. We have previously published on the RMI-3 in a subgroup of the present study population.15 
Ultrasound was performed transvaginally combined with abdominal ultrasound when needed, 
by experienced gynaecologic oncologists, general gynaecologists, or registrars in gynaecology. 
Serum samples were analysed for CA 125 as part of routine preoperative assessment, and 
menopausal status was registered. Based on the data obtained, the RMI-3 was calculated 
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prospectively as the multiplied value of the ultrasound score (U), menopausal status (M) and 
serum CA 125 level as follows: 
RMI-33 = U x M x CA 125. Multilocularity, solid areas, bilaterality, ascites and intra-abdominal 
metastases score one point each. A total of 2 or more points was recalculated into U=3, fewer than 
2 points into U=1. Postmenopausal status is defined as more than 1 year of amenorrhoea, or age 
50 years or older among women who had prior hysterectomies, and scores M=3; premenopausal 
status scores M=1. Serum CA 125 (U/mL) was entered directly into the equation. 
Based on the obtained data, RMI-4 was calculated retrospectively as follows: 
RMI-416 = U x M x S x CA 125. A total ultrasound score of 0 or 1 was recalculated into U=1, and 
a score of ≥2 into U=4. Premenopausal status scores M=1 and postmenopausal status scores 
M=4. The tumour size was obtained from the pathology report. A tumour size (single greatest 
diameter) of <7 cm was recalculated into S=1, and ≥7 cm into S=2, as introduced by Yamamoto et 
al.16 The serum CA 125 (U/mL) was applied directly to the calculation.
Final diagnoses of included patients were based on the histopathological examination of 
surgical specimens. Patients that were diagnosed with non-gynaecological malignancies were 
excluded from the study. The RMI was merely registered and not applied in a standardised 
manner in the further planning of care. Based on the clinical impression by the gynaecologist 
in the local hospital it was decided whether a gynaecologic oncologist should be involved in 
the surgical treatment. This clinical impression was based on routine preoperative assessment, 
consisting of physical examination, testing of serum samples, and ultrasound examination. The 
local gynaecologists varied in levels of expertise, from gynaecologists specialised in oncology to 
general gynaecologists. 
Statistical analyses were performed using the Statistical Packages for the Social Sciences Version 
16.0.1 (SPSS Inc., Chicago, IL). The sensitivity, specificity, positive and negative predictive values, 
and accuracy of RMI-3 and RMI-4 were calculated. Borderline malignancies were allocated to the 
non-invasive group in all analyses. Comparison between patients with non-invasive (benign and 
borderline) lesions and invasive malignancies was performed using the Mann–Whitney U test 
for age and serum CA 125 level, the Pearson χ2 test for menopausal status and tumour size and 
the Kruskal–Wallis test for ultrasound score. A receiver operating characteristic (ROC) curve was 
created to show the relation between sensitivity and specificity of both RMI-3 and RMI-4 in the 
discrimination between non-invasive lesions and invasive malignancies, and an area under the 
curve (AUC) was calculated for both models. The McNemar’s test was used to test the difference 
in performances between RMI-3 and RMI-4. The cut-off level was set at 200 for RMI-3 and 450 for 
RMI-4 to be able to compare the results with the study of Yamamoto et al.16 A p-value ≤ .05 was 
considered as statistically significant.
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RESULTS
A total of 643 patients was included in the study, of whom 469 (73%) were diagnosed with 
benign ovarian cysts, 73 patients (11%) with borderline malignancies, and 101 patients (16%) 
with malignant diseases. The distribution of age, menopausal status, ultrasound score, tumour 
size and serum CA 125 level in the non-invasive and invasive groups was as shown in Table 1. 
Statistically significant differences between the two groups were observed for all these variables. 
The histopathological diagnoses are listed in Table 2. The majority of non-invasive gynaecological 
conditions included mucinous cystadenomas (n=118) and serous cystadenomas (n=86). Histo-
pathological diagnoses in invasive malignant diseases were mainly serous cystadenocarcinomas 
(n=41). 
Table 1. Distribution of age, menopausal status, ultrasound score, tumour size and serum CA 125 levels in 643 
patients with non-invasive lesions (n=542) and invasive malignant (n=101) adnexal masses.
  
Characteristic
Non-invasive lesions
(n=542)
Invasive malignancies
(n=101)
Significance level (p)
Age (years)
Median (range) 55 (13-93) 60 (24-85) .008b
Postmenopausal
n (%) 327 (60%) 73 (72%) .023c
Ultrasound scorea
0 
n (%)
1
n (%)
2-5
n (%)
129 (24%)
210 (39%)
203 (37%)
2 (2%)
19 (19%)
80 (79%)
.000d
Tumour size
<7 cm
n (%)
≥7 cm
n (%)
204 (38%)
338 (62%)
18 (18%)
83 (82%)
.000c
Serum CA 125 (U/mL)
Median (range) 18 (2-2914) 153 (7-7800) .000b
a Ultrasounds were scored one point for each of the following characteristics: multilocularity, solid areas, 
bilaterality, ascites and intra-abdominal metastases.
b Mann-Whitney U test.
c Pearson χ2 test.
d Kruskal-Wallis test.
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The performances of the RMI-3 and RMI-4 at various cut-off levels are presented in Table 3. At 
a cut-off level of 200, the RMI-3 gave a sensitivity of 76% and a specificity of 82%. Positive and 
negative predictive values at that cut-off level were 45% and 95%, respectively. The accuracy 
was 81%. The RMI-4 gave, at a cut-off level of 450, a sensitivity of 74% and a specificity of 79%. 
Positive and negative predictive values at that cut-off level were 40% and 94%, respectively. The 
accuracy was 78%. 
The diagnostic performances of both RMI-3 and RMI-4 are illustrated in Fig. 1. A comparison of 
the accuracy levels of the two indices showed that RMI-3 at a cut-off level of 200 was significantly 
better in predicting invasive malignancy than RMI-4 at a cut-off level of 450 (p=.001). Both models 
had an area under the curve of 0.86.
Table 2. Distribution of histopathological diagnoses.
n %
Noninvasive lesions (n=542)
Mucinous cystadenomas
Serous cystadenomas
Other cystadenomas
Simple cysts
Fibroma
Dermoids
Endometriotic cysts
Mucinous borderline
Serous borderline
Others
118
86
14
66
57
49
40
40
29
43
22
16
3
12
11
9
7
7
5
8
Invasive malignancies (n=101)
Serous cystadenocarcinomas
Mucinous cystadenocarcinomas
Endometrioid adenocarcinomas
Undifferentiated adenocarcinomas
Clear cell carcinomas
Carcinosarcomas
Granulosa cell tumors
Others
41
10
12
15
14
3
3
3
40
10
12
15
14
3
3
3
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Table 3. Performances of RMI-3 and RMI-4 at various cut-off levels. 
Cut-off Sensitivity (%) Specificity (%) PPV (%) NPV (%) Accuracy (%)
RMI-3 RMI-4 RMI-3 RMI-4 RMI-3 RMI-4 RMI-3 RMI-4 RMI-3 RMI-4 RMI-3 RMI-4
100
120
200
250
300
350
400
450
500
550
81
78
76
72
68
76
75
74
73
73
68
76
82
86
87
75
77
79
81
82
32
38
45
49
50
36
37
40
41
43
95
95
95
94
94
94
94
94
94
94
70
76
81
84
84
75
76
78
79
81
RMI, Risk of Malignancy Index; PPV, positive predictive value; NPV, negative predictive value. 
Figure 1. Receiver operating characteristic curves of the Risk of Malignancy Index-3 and Risk of Malignancy 
Index-4 showing the relation between sensitivity and specificity in the discrimination between non-invasive 
lesions and invasive malignancies. The area under the curve is 0.86 for RMI-3 and 0.86 for RMI-4.
Footnote: RMI, Risk of Malignancy Index.
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COMMENT 
This study has confirmed that both RMI-3 and RMI-4 were able to discriminate between non-
invasive lesions and invasive malignant masses. The RMI-4 tested on a new population of women 
with adnexal masses showed lower sensitivity and specificity levels compared with the original 
report.16 External validation of proposed models often results in a decreased performance 
compared to the performance that is reported initially.8 Therefore, external validation of a 
prediction model is essential before introduction into clinical practice. In this new population 
both RMI-3 and RMI-4 were able to discriminate between non-invasive lesions and invasive 
malignant adnexal masses, with similar performances. Although the accuracy was higher in RMI-
4, the similar AUC and overlapping ROC curves indicate that the differences in performances are 
not statistically significant.
We have chosen to use the RMI-33 over the original RMI1 or RMI-2.2 The reason for eliminating 
RMI-1 is that it gives an ultrasound score (U) of 0 when none of the ultrasound features were 
present. This results in an RMI of 0 regardless of the CA 125 level, whereas we consider the CA 
125 level as an important parameter of the RMI. CA 125 level does contribute in both RMI-2 and 
RMI-3. We decided to use the RMI-3 because it has been evaluated more extensively than RMI-2. 
Yamamoto et al.16 have allocated borderline malignancies to the malignant group, whereas we 
chose to allocate the borderline tumours to the benign group. The primary goal for developing 
the RMI is the accurate referral of patients with invasive malignant diseases to gynaecologic 
oncologists. Although some borderline malignancies with invasive implants may require 
significant gynaecological oncological debulking, more than 90% of cases are stage I tumours 
and most cases behave in a benign fashion.10 Women with these borderline malignancies do 
not necessarily have to undergo aggressive surgical treatment by a gynaecologic oncologist to 
optimize their survival chances. This difference in allocation of the borderline tumours however, 
does not explain the different results between the two studies. When we confer the borderline 
malignancies as malignant in our dataset, the accuracy of RMI-3 and RMI-4 detoriate to 77% and 
76%, respectively. RMI-3 still performs better than RMI-4, but the difference is not statistically 
significant anymore. 
Yamamoto et al.16 have measured tumour size by ultrasound for each patient, whereas we have 
extracted this information from the pathology report. In daily clinical practice ultrasound would 
be used, because this is the only parameter on size that is available preoperatively. Although 
there is no evidence in literature, measurements by ultrasound and by pathology report are 
expected to be highly correlated. By applying the RMI-4 retrospectively on our dataset we were 
able to rapidly produce an external validation on the RMI-4 in a high number of patients. Future 
analysis in a prospective study may however still be needed to validate the RMI-4 as a new tool.
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The additional value of tumour size in predicting ovarian malignancy is debatable. Tumour size is 
not considered an independent predictor of malignancy in ovarian tumours in literature. Recently, 
McDonald et al.17 have assessed several tumour variables for their correlation with malignancy. 
Tumour size with a cut-off level of 10 cm was statistically related to the risk of malignancy, 
however it was not indicated as a significant factor after a multivariable analysis. Using the cut-
off level of 10 cm for the tumour size variable did not improve the performance of RMI-4 in our 
study population. Unfortunately, Yamamoto et al. did not explain their decision to add tumour 
size in the RMI. We do not know if they have performed a multivariable analysis to establish that 
tumour size is an independent predictor of malignancy. Why they have dichotomised the tumour 
size variable with a cut-off level of 7 cm is also not known. In our study population, the majority of 
patients with non-invasive lesions (62%) had a tumour size larger than 7 cm. In case the tumour 
size is included in the RMI, all these women with benign lesions end with a doubled RMI score 
compared with the situation where the tumour size was not included in the RMI.
In conclusion, this external validation showed that RMI-3 and RMI-4 perform similar in predicting 
invasive malignancy. Our findings have reconfirmed the ability of the RMI to discriminate 
between non-invasive lesions and invasive malignant masses. At this moment, we do not see 
any advantage in introducing an adapted version of the RMI that includes tumour size in the 
preoperative assessment of adnexal masses.
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ABSTRACT 
Objective
To determine the factors that influence the use of frozen section analysis in adnexal masses and 
the factors that predict malignancy.
Methods
The study participants were women scheduled for adnexal mass surgery in 11 hospitals 
between 2005 and 2009. Factors that potentially influenced the use of frozen section analysis 
and potentially predicted malignancy were studied, such as menopausal status, CA 125 level, 
ultrasound characteristics, presence of adhesions, and tumour size. We used univariable and 
multivariable analyses to assess the factors. 
Results
A total of 670 patients were included in the study. The frozen section analyses for 323 patients 
(48%) showed 206 benign, 55 borderline, and 62 malignant adnexal masses. The CA 125 level, 
locularity of the tumour, and presence of solid areas predicted both the use of frozen section 
analysis and the presence of malignancy. The presence of adhesions predicted malignancy, but 
not the use of frozen section analysis. Menopausal status and tumour size predicted the use of 
frozen section analysis, but not malignancy.
Conclusion
Menopausal status and tumour size are associated with more use of frozen section analysis, but 
they have not been identified as factors associated with malignancy. Frozen section analysis 
is useful when the CA 125 levels are greater than 35 units/mL and when there are multilocular 
tumours, solid areas on ultrasonography, and adhesions revealed during surgery.
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INTRODUCTION
Frozen section analysis is widely used in the intraoperative evaluation of adnexal masses, and it 
is often useful to determine the appropriate surgical strategy. The discriminative preoperative 
evaluation of adnexal masses is rather complex. Various diagnostic models, such as the Risk of 
Malignancy Index1-3, are used in the preoperative work-up. Despite all efforts, the interpretation 
of the nature of the adnexal mass is often inaccurate. The prospective, randomised, controlled 
study by Yazbek et al.4 showed that the quality of gynaecological ultrasonography has a 
significant influence on the management of patients with suspected ovarian cancer. Experienced 
sonographers diagnosed benign adnexal pathology more accurately. 
Intraoperative pathologic examination aids in making an informed decision for determining the 
extent of surgery and helps prevent both undertreatment and overtreatment. This is especially 
important for young women who may be managed conservatively with preservation of fertility.
Frozen section analysis is generally accepted as a reliable method for determining the nature of 
an adnexal mass. The accuracy in detecting invasive malignancies has been assessed in previous 
studies. A systematic review by Geomini et al.5 showed high levels of sensitivity and specificity 
(71–100% and 98–100%, respectively) for frozen section analysis. In contrast, frozen section 
analysis of borderline adnexal masses appears to be less accurate. Tempfer et al.6 presented a 
pooled analysis of four studies that included 317 women with borderline adnexal masses. The 
overall sensitivity was 71.1% and the positive predictive value was 84.3%.
It might be wise to analyse frozen sections from all patients with adnexal masses to obtain as 
much information as possible for determining the optimal surgical procedure. However, analysing 
frozen sections extends the operating time and thus the duration of anaesthesia. Furthermore, 
frozen section analysis increases costs and implies a heavier workload for pathologists.
Most gynaecologists decide before surgery whether frozen section analysis is needed, and they 
may alter the decision during surgery, depending on the intraoperative findings. Various factors 
influence the surgeon’s use of frozen section analysis, depending on the suspicion of malignancy.7 
The objective of this study was to determine the factors that influence the use of frozen section 
analysis in adnexal masses and the factors that predict malignancy.
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MATERIALS AND METHODS
This retrospective cohort study was conducted in the Radboud University Nijmegen Medical 
Center (RUNMC) and 10 cooperating referral hospitals in the east of the Netherlands between 
January 2005 and September 2009. The study was approved by the medical ethics committee 
of the RUNMC. Women who were admitted for surgical treatment of an adnexal mass with 
unknown histology were included in the study. A subgroup (n=548) of the study population has 
been described in our previous publication about the Risk of Malignancy Index.3 The patients for 
whom frozen section analysis was cancelled were excluded from participation in this study if 
there was clear evidence of malignancy during the surgical procedure, such as pleural effusions 
and evidence of distal organ involvement. 
Menopausal status was registered. Ultrasonography for assessing the locularity of the tumour, 
laterality, and presence of solid areas, and the determination of the serum level of CA 125 
were all parts of the routine preoperative evaluation. All ultrasonography was performed by 
experienced sonographers. Ultrasonography was performed transvaginally and was combined 
with abdominal ultrasonography if necessary. Doppler flow studies were not performed. No 
ultrasound morphologic grading system was used. The presence of adhesions and the diameter 
of the tumour were retrospectively obtained from the surgery and pathology reports. The use 
of frozen section analysis was registered, as was the corresponding histopathologic outcome. 
The final diagnosis of the adnexal mass was based on the full histopathologic examination of all 
surgical specimens removed. A total of six pathology units covered the pathology activities of the 
11 hospitals that participated in this study. One of these units covered four hospitals, two units 
each covered two hospitals, and three units each covered one hospital.
The histopathologic diagnosis of the frozen section analysis was compared with the final 
histopathology. The sensitivity, specificity, and the positive and negative predictive values of 
frozen section analysis for malignant tumours were calculated. Factors that potentially influenced 
the use of frozen section analysis and potentially predicted the presence of malignancy, including 
menopausal status, CA 125 level, ultrasound characteristics, presence of adhesions, and tumour 
size, were studied. We used univariable logistic regression to study the ability of the variables 
to predict the use of frozen section analysis and to predict invasive malignancy in patients with 
adnexal masses. We used multivariable logistic regression with stepwise selection procedures to 
identify variables that contributed independently to the use of frozen section analysis and to the 
presence of invasive malignancy. All variables that reached the level of significance at 0.10 in the 
univariable logistic regression were valid for entry in the selection procedure, and we used P=.05 
for staying in the model. We used SPSS 16.0.1 for Windows for all statistical analyses.
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RESULTS
During the study period, 722 women underwent surgery for an adnexal mass, and 670 (93%) 
were included in the study. The 52 women (7%) for whom frozen section analysis was cancelled 
because of clear evidence of malignancy during the surgical procedure were excluded from the 
study. Of the 670 participants, 531 (80%) had benign gynaecological conditions diagnosed (i.e., 
final histopathologic diagnosis), 70 (10%) had borderline malignancy diagnosed, and 69 (10%) 
had malignant disease diagnosed. General gynaecologists performed the surgery for 503 women 
(75%), gynaecologic oncologists performed the surgery for 53 women (8%), and either a general 
gynaecologist or a gynaecologic oncologist performed the surgery for 114 women (17%).
Frozen sections were analysed for 323 patients (48%); 206 of these sections (64%) showed 
benign ovarian cysts, 55 (17%) showed borderline malignancies, and 62 (19%) showed malignant 
adnexal masses. Frozen sections were analysed for 39% of the benign ovarian cysts, for 79% of 
the borderline malignancies, and for 90% of the malignant adnexal masses. Table 1 presents the 
characteristics and final histologic types of all the cases in relation to frozen section analysis.
The adnexal masses of seven patients without frozen section analysis were identified as 
malignant only after the final histopathologic examination (10%). Five of these patients were 
postmenopausal and two were premenopausal. Three of the seven patients presented with 
a multilocular mass and solid areas on ultrasonography. One of them had a CA 125 level of 
60 units/mL, and another presented with adhesions during surgery. Two patients presented 
with multilocularity only on ultrasonography. One patient presented with solid areas only on 
ultrasonography and one presented with only a CA 125 level of 40 units/mL.
Table 2 shows the comparison of frozen section analysis with the final histopathologic diagnosis. 
The frozen section analysis was concordant with the final pathology findings for 292 patients 
(90%). The sensitivity, specificity, and positive and negative predictive values of frozen section 
analysis were 84% (95% confidence interval [CI] 75–93%), 99% (95% CI 98–100%), 95% (95% CI 
89–100%), and 96% (95% CI 94–98%), respectively, for malignant tumours. The accuracy was 
96% (95% CI 94–98%).
Table 3 shows factors that potentially influence the use of frozen section analysis or predict the 
presence of malignancy. In a univariable analysis, all factors tested were significant predictors of 
the use of frozen section analysis. Predictive factors for the presence of malignancy were the CA 
125 level, locularity of the tumour, bilaterality, presence of solid areas, presence of adhesions, 
and diameter of the tumour.
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Table 1. Characteristics and final histopathologic classification in the groups of women with and without 
frozen section analysis performed.
 
 
Characteristic
 
Total
(N=670)
Frozen section 
analysis 
performed
(n=323)
Frozen section 
analysis not 
performed
(n=347)
Age (y) 54 (13-93) 58 (13-93) 50 (16-87)
Postmenopausal 390 (58) 217 (67) 173 (50)
Serum CA 125 (units/mL) 20 (2-2,914) 29 (3-2,914) 14 (2-442)
Histopathologic type
Benign 
Mucinous cystadenomas
Serous cystadenomas
Other cystadenomas
Simple cysts
Endometriotic cysts
Dermoids
Fibroma 
Other benign diseases
Borderline 
Mucinous borderline
Serous borderline
Other borderlines
Malignant 
Serous cystadenocarcinomas
Mucinous cystadenocarcinomas
Endometrioid adenocarcinomas
Undifferentiated adenocarcinomas
Clear cell carcinomas
Carcinosarcomas
Granulosa cell tumours
Other invasive malignancies
531 (80)
124
92
12
78
57
56
56
56
70 (10)
37
28
5
69 (10)
24
8
12
5
12
2
3
3
206 (40)
69 (56)
32 (35)
6 (50)
19 (24)
16 (28)
14 (25)
34 (61)
16 (29)
55 (79)
29 (78)
21 (75)
5 (100)
62 (90)
21 (88)
7 (88)
12 (100)
4 (80)
11 (92)
2 (100)
3 (100)
2 (67)
325 (60)
55 (44)
60 (65)
6 (50)
59 (76)
41 (72)
42 (75)
22 (39)
40 (71)
15 (21)
8 (22)
7 (25)
0 (0)
7 (10)
3 (12)
1 (12)
0 (0)
1 (20)
1 (8)
0 (0)
0 (0)
1 (33)
Data are median (range) or n (%).
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Table 2. Frozen section analysis and final histopathologic diagnosis in women with adnexal masses.
Frozen section analysis
Final histopathology Malignant Borderline Benign Undecided Total
Malignant
Borderline
Benign
Total
52 (84)
2 (4)
1 (1)
55
7 (11)
42 (76)
7 (3)
56
2 (3)
10 (18)
198 (96)
210
1 (2)
1 (2)
0 (0)
2
62
55
206
323
Data are n (%) or n.
Table 3. Crude odds ratios with 95% confidence interval of variables predicting the use of frozen section 
analysis and predicting invasive malignancy in women with adnexal masses using univariable logistic 
regression.
Frozen section analysis 
performed
Invasive malignancy*
Variable Total N n (%) OR (95% CI) n (%) OR (95% CI)
Menopausal status
Premenopausal
Postmenopausal
280
390
106 (38)
217 (56)
1.00 (reference)
2.06 (1.51-2.82)
22 (8)
47 (12)
1.00 (reference)
1.61 (0.94-2.73)
CA 125
Less than 35 units/mL
35 units/mL or more
455
207
171 (38)
150 (72)
1.00 (reference)
4.37 (3.05-6.26)
17 (4)
51 (25)
1.00 (reference)
8.42 (4.72-15.02)
Locularity of the tumour
Unilocular
Multilocular
277
393
89 (32)
234 (60)
1.00 (reference)
3.11 (2.25-4.29)
16 (6)
53 (14)
1.00 (reference)
2.54 (1.42-4.55)
Laterality of the tumour
Unilateral
Bilateral
604
66
282 (47)
41 (62)
1.00 (reference)
1.87 (1.11-3.16)
55 (9)
14 (21)
1.00 (reference)
2.69 (1.40-5.16)
Presence of solid areas
No
Yes
330
340
103 (31)
220 (65)
1.00 (reference)
4.04 (2.93-5.58)
11 (3)
58 (17)
1.00 (reference)
5.97 (3.07-11.59)
Presence of adhesions
No
Yes
425
218
192 (45)
123 (56)
1.00 (reference)
1.57 (1.13-2.18)
29 (7)
37 (17)
1.00 (reference)
2.79 (1.67-4.68)
Diameter of the tumour
Smaller than 5 cm
5 – 10 cm
10 – 25 cm
25 cm or larger
120
199
242
42
23 (19)
63 (32)
183 (76)
38 (91)
1.00 (reference)
1.95 (1.13-3.37)
13.08 (7.62-22.47)
40.07 (12.99-123.54)
3 (3)
14 (7)
44 (18)
3 (7)
1.00 (reference)
2.95 (0.83-10.49)
8.67 (2.63-28.54)
3.00 (0.58-15.48)
OR, odds ratio; CI, confidence interval.
* Based on the full histopathologic examination of all surgical specimens removed.
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Table 4 shows the multivariable regression analyses used to identify independent predictive 
factors for frozen section analysis use and for the presence of malignancy. The CA 125 level, 
locularity of the tumour, and the presence of solid areas were predictors of both the use of 
frozen section analysis and the presence of malignancy. The presence of adhesions predicted 
malignancy, but not the use of frozen section analysis. In contrast, menopausal status and 
tumour size were predictors of the use of frozen section analysis, but not of malignancy.
Table 4. Adjusted odds ratios with 95% confidence interval of variables predicting the use of frozen section 
analysis and predicting invasive malignancy in women with adnexal masses using multivariable logistic 
regression with stepwise selection procedures.
 
Factor
Frozen section analysis performed 
OR (95% CI)
Invasive malignancy* 
OR (95% CI)
Menopausal status
Premenopausal
Postmenopausal
1.00 (reference)
1.98 (1.26-3.12)
Not selected
CA 125
Less than 35 units/mL
35 units/mL or more
1.00 (reference)
3.44 (2.09-5.65)
1.00 (reference)
6.62 (3.46-12.82)
Locularity of the tumour
Unilocular
Multilocular
1.00 (reference)
2.23 (1.43-3.45)
1.00 (reference)
2.56 (1.15-4.42)
Presence of solid areas
No
Yes
1.00 (reference)
4.42 (2.85-6.90)
1.00 (reference)
3.73 (1.79-7.75)
Presence of adhesions
No
Yes
Not selected
1.00 (reference)
2.20 (1.21-4.00)
Diameter of the tumour
Smaller than 5 cm
5–10 cm
10–25 cm
25 cm or larger
1.00 (reference)
1.10 (0.99-3.28)
10.38 (5.69-18.97)
32.72 (9.97-107.36)
Not selected
OR, odds ratio; CI, confidence interval.
The variables valid for entry in the model in both selection procedures were menopausal status, CA 125 
level, locularity of the tumour, laterality of the tumour, presence of solid areas, presence of adhesions, and 
diameter of the tumour.
* Based on the full histopathologic examination of all surgical specimens removed.
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DISCUSSION
Intraoperative frozen section analysis is an important and reliable tool in the clinical management 
of patients with adnexal masses. The main problem in this management is the risk of malignancy, 
which is why adnexal masses have to be carefully assessed before surgery. As reported in previous 
publications,5,8,9 frozen section analysis is a reliable method for detecting invasive malignancies 
during the operative procedure. In our study, we found high levels of sensitivity (84%) and positive 
predictive value (95%), which are comparable with those of previous studies.5,8,9 Little information 
has been published concerning the factors that influence the decision to analyse a frozen section 
during adnexal mass surgery. We therefore have investigated which factors influence the use of 
frozen section analysis in adnexal masses and which factors predict malignancy.
In the recent study by Brun et al.,7 patient age older than 50 years, tumour size larger than 10 
cm, and preoperative evidence of malignancy were associated with more use of frozen section 
analysis. We also have identified tumour size as an independent predictive factor for using frozen 
section analysis. Other factors influencing the use of frozen section analysis in our study were 
the CA 125 level, locularity of the tumour, and presence of solid areas. Tumour size predicted 
the use of frozen section analysis, but not the presence of malignancy. This is compatible with 
the literature, because tumour size is generally not considered an independent predictor of 
malignancy.10
In our cohort, frozen sections were more often analysed for postmenopausal women, but 
menopausal status was not identified as an independent predictor of malignancy. This conflicts 
with data on the Risk of Malignancy Index that identified postmenopausal status as an 
independent risk factor for malignancy.1 Women for whom frozen section analysis was cancelled 
because of clear evidence of malignancy during the surgical procedure were excluded from the 
study. These women, however, were more often postmenopausal than the women in our study 
group (83% compared with 58%). This might have caused a selection bias. Furthermore, it might 
be possible that menopausal status would have been identified as an independent predictor 
of malignancy in a larger sample size. Adhesions revealed during surgery were associated 
with malignancy. However, adhesions did not lead to more use of frozen section analysis. The 
presence of adhesions is the only variable that cannot be assessed reliably preoperatively; it has 
to be assessed during surgery. Although we do not have all the necessary information, the data 
suggest that the decision to analyse a frozen section is more often based on the preoperative 
findings than intraoperative ones, or that the presence of adhesions is an underestimated 
predictor of malignancy. 
Unfortunately, whether ascites was present was unknown for 68% of the patients. Therefore, 
we were unable to determine whether the presence of ascites is a predictor of analysing frozen 
sections to determine malignancy. The presence of ascites could indicate malignancy and 
probably has an effect on the management of these cases.
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The malignancies of seven patients (which represent 10% of all malignancies) were not found 
intraoperatively. Six of these patients were wrongly diagnosed with benign diseases; therefore, 
they were not properly staged. Analysing frozen sections would have been of great value in these 
cases. The surgeon suspected malignancy in one case but decided that the patient would not be a 
suitable candidate for radical surgery. Therefore, minimally invasive surgery was performed and 
several biopsies were performed. In this case, frozen section analysis would not have changed the 
management approach.
Frozen section analysis has its limitations. It is not accurate in all cases. A report by Geomini et 
al.11 showed that tumour size has an effect on the accuracy of frozen section analysis. For masses 
with a diameter of 10 cm or larger, a benign result of the frozen section analysis was less reliable 
than for masses with a diameter of less than 10 cm. In the group with masses of 10 cm or more, 
11% of the women for whom frozen section analysis indicated a benign cyst turned out to have a 
malignant or borderline tumour according to the final pathology. Not only tumour size but also 
the mucinous histologic type limits the accuracy of frozen section analysis.5,9,12,13
Frozen section analysis is not always useful. If the probability of malignancy is low before surgery, 
then it is unlikely that frozen section analysis will change the clinical management. This is also 
true when the malignancy becomes evident before or during surgery. It is important that the use 
of frozen section analysis is considered carefully in each case to avoid superfluous testing, but it 
also should be used when necessary to determine the extent of the surgical procedure.
In conclusion, menopausal status and tumour size are associated with more use of frozen section 
analysis, but they have not been identified as factors associated with malignancy. The frozen 
section analysis is useful when the CA 125 levels are greater than 35 units/mL and when there are 
multilocular tumours, solid areas on ultrasonography, and adhesions revealed during surgery.
FINANCIAL DISCLOSURE
The authors did not report any potential conflicts of interest.
61
Factors influencing the use of frozen section analysis in adnexal masses
4
REFERENCES
1.	 Jacobs	 I,	 Oram	 D,	 Fairbanks	 J,	 Turner	 J,	 Frost	 C,	 Grudzinskas	 JG.	 A	 risk	 of	 malignancy	 index	
incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis 
of ovarian cancer. Br J Obstet Gynaecol 1990;97:922-9.
2. Tingulstad S, Hagen B, Skjeldestad FE, Halvorsen T, Nustad K, Onsrud M. The risk-of-malignancy 
index	to	evaluate	potential	ovarian	cancers	in	local	hospitals.	Obstet	Gynecol	1999;93:448-52.
3. van den Akker PA, Aalders AL, Snijders MP, Kluivers KB, Samlal RA, Vollebergh JH, et al. Evaluation 
of	the	Risk	of	Malignancy	Index	in	daily	clinical	management	of	adnexal	masses.	Gynecol	Oncol	
2010;116:384-8.
4.	 Yazbek	J,	Raju	SK,	Ben-Nagi	J,	Holland	TK,	Hillaby	K,	Jurkovic	D.	Effect	of	quality	of	gynaecological	
ultrasonography on management of patients with suspected ovarian cancer: a randomised 
controlled trial. Lancet Oncol 2008;9:124-31.
5. Geomini P, Bremer G, Kruitwagen R, Mol BW. Diagnostic accuracy of frozen section diagnosis of 
the	adnexal	mass:	a	metaanalysis.	Gynecol	Oncol	2005;96:1-9.
6.	 Tempfer	CB,	Polterauer	S,	Bentz	EK,	Reinthaller	A,	Hefler	LA.	Accuracy	of	 intraoperative	 frozen	
section analysis in borderline tumors of the ovary: a retrospective analysis of 96 cases and review 
of the literature. Gynecol Oncol 2007;107:248-52.
7.	 Brun	 JL,	Cortez	A,	Rouzier	R,	Callard	P,	Bazot	M,	Uzan	S,	et	al.	 Factors	 influencing	 the	use	and	
accuracy of frozen section diagnosis of epithelial ovarian tumors. Am J Obstet Gynecol 2008:244.
e1-.e7.
8. Medeiros LR, Rosa DD, Edelweiss MI, Stein AT, Bozzetti MC, Zelmanowicz A, et al. Accuracy of 
frozen-section analysis in the diagnosis of ovarian tumors: a systematic quantitative review. Int J 
Gynecol Cancer 2005;15:192-202.
9. Ilvan S, Ramazanoglu R, Ulker AE, Calay Z, Bese T, Oruc N. The accuracy of frozen section 
(intraoperative consultation) in the diagnosis of ovarian masses. Gynecol Oncol 2005;97:395-9.
10. McDonald JM, Doran S, DeSimone CP, Ueland FR, DePriest PD, Ware RA, et al. Predicting risk of 
malignancy	in	adnexal	masses.	Obstet	Gynecol	2010;115:687-94.
11.	 Geomini	PM,	Zuurendonk	LD,	Bremer	GL,	de	Graaff	J,	Kruitwagen	RF,	Mol	BW.	The	impact	of	size	
of	the	adnexal	mass	on	the	accuracy	of	frozen	section	diagnosis.	Gynecol	Oncol	2005;99:362-6.
12. Rose PG, Rubin RB, Nelson BE, Hunter RE, Reale FR. Accuracy of frozen-section (intraoperative 
consultation) diagnosis of ovarian tumors. Am J Obstet Gynecol 1994;171:823-6.
13.	 Puls	L,	Heidtman	E,	Hunter	JE,	Crane	M,	Stafford	J.	The	accuracy	of	frozen	section	by	tumor	weight	
for ovarian epithelial neoplasms. Gynecol Oncol 1997;67:16-9.

Petronella A.J. van den Akker
Petra L.M. Zusterzeel
Anette L. Aalders
Marc P.L.M. Snijders
Rahul A.K. Samlal
Jos H.A. Vollebergh
Kirsten B. Kluivers
Leon F.A.G. Massuger
International Journal of Gynecology and Obstetrics, in press
Use of Risk of Malignancy Index to indicate 
frozen section analysis in the surgical care of 
women with ovarian tumours
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ABSTRACT
Objective
To evaluate the importance of the Risk of Malignancy Index (RMI) in the decision to perform 
frozen section analysis among women with ovarian tumours.
Methods
A retrospective study was conducted in 11 centres in the Netherlands. Women who underwent 
surgical treatment of an ovarian mass with unknown histology between January 2005 and 
September 2009 were included. The RMI was calculated retrospectively. Frozen section analysis 
and RMI values were assessed for patients with benign, borderline, and malignant ovarian 
tumours on final histopathology.
Results
Overall, 670 women were included. Frozen sections were performed in 323 (48.2%) patients, 
of whom 206 (63.8%) were diagnosed with benign ovarian tumours, 55 (17.0%) with borderline 
tumours, and 62 (19.2%) with malignant tumours. Overall, 109 (16.3%) women had an RMI below 
20, 106 (97.2%) of whom had benign histology results. Among 235 patients with an RMI over 100, 
3 (1.3%) postmenopausal women had malignancies that were missed because frozen sections 
were not performed.
Conclusion
Women with an RMI below 20 have a low risk of malignancy and therefore do not require frozen 
section analysis. Postmenopausal women with an RMI greater than 100 should be referred to 
centres where frozen sections can be performed, and proper facilities and expertise are available 
to perform staging procedures if necessary.
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INTRODUCTION
The differentiation between benign and malignant histology is crucial in the management of 
women with ovarian tumours. Along with surgical expertise, accurate histological assessment 
before surgery, which usually includes ultrasonography, is important in counselling and 
preoperative planning of the surgical approach. The Risk of Malignancy Index  (RMI)—the 
first simple diagnostic index suitable for use in clinical practice and which defines the optimal 
combination of diagnostic criteria—was developed by Jacobs et al.1 to standardize and improve 
the preoperative evaluation of ovarian tumours. A RMI cut-off value of 200 is generally used to 
discriminate between benign and malignant ovarian tumours. 
Among women with ovarian cancer, surgical staging and optimal cytoreductive surgery are 
essential and result in improved survival.2,3 If the ovarian tumour is benign, a more conservative 
approach—e.g. one-sided salpingo-oophorectomy or cystectomy—will suffice and can contribute 
to fertility preservation for young women. Nevertheless, despite careful interpretation, current 
diagnostic procedures do not allow a definitive diagnosis of ovarian cancer to be established 
preoperatively, merely suggest its presence instead.4,5 Frozen section analysis could assist in 
informed decision making to determine the extent of surgery required and prevent undertreatment 
or overtreatment. Because of its utility and the limited value of preoperative diagnostics, frozen 
section analysis is frequently used for ovarian tumours. Indeed, the recommended rate of frozen 
section analysis in general surgical practice is 5%–15%,6,7 whereas for ovarian tumours, rates 
range from 19% to 66%.8-10
The accuracy of frozen section analysis is generally good and has been thoroughly assessed in 
previous studies.11-13 A systematic review by Geomini et al.11 showed that frozen section analysis 
achieves a sensitivity of 71%–100% and a specificity of 98%–100% in malignancy detection. 
By contrast, frozen section analysis of borderline adnexal masses13,14 and mucinous histologic 
tumour types,11,15 seems to be less accurate. In 2012, Cross et al.16 used frozen section analysis for 
suspected early ovarian cancer and showed an excellent diagnostic test accuracy, concluding that 
frozen section analysis assisted gynaecologic oncologists to perform the appropriate surgery in 
95% of cases. Nevertheless, it should be noted that their study population consisted of women 
with an RMI of 200 and higher. Further, some retrospective studies17,18 have suggested that the 
accuracy of frozen section analysis improves when performed by an expert pathologist.
The objective of the present study was to evaluate the importance of the RMI in the decision to 
perform frozen section analysis among women with ovarian tumours.
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MATERIALS AND METHODS
A retrospective study was conducted in Radboud University Medical Center (Radboudumc) and 
10 cooperating community hospitals in the east of the Netherlands. Women who were admitted 
for surgical treatment of an ovarian mass with unknown histology between January 1, 2005, and 
September 30, 2009, were included. Women in whom clear evidence of malignancy was found 
before or during the surgical procedure (e.g. pleural effusions and evidence of distal organ 
involvement) were excluded. Part of this study population has been previously described.19-21 
The study was approved by the medical ethics committee of the Radboudumc. Written informed 
consent was not required because data were abstracted retrospectively from patient files and 
stored anonymously in a database.
Transvaginal ultrasonography, combined with abdominal ultrasonography when needed, was 
performed by experienced echoscopists (all medical doctors). Routine preoperative assessment 
included analysis of serum samples for cancer antigen 125 (CA 125), and menopausal status was 
recorded. Patient RMI parameters were registered by gynaecologists as was requested for a 
previous study.19 The RMI was calculated as the multiplied value of the ultrasonography score 
(U), menopausal status (M), and serum CA 125 level (U/mL) as described by Tingulstad et al.:22 
RMI = U × M × CA 125. With regard to U, multilocularity, solid areas, bilaterality, ascites, and 
intra-abdominal metastases were scored as one point each; U = 3 was assigned to a total of 2 
or more points and U=1 to fewer than 2 points. With regard to M, a postmenopausal status was 
defined as more than 1 year of amenorrhea or age 50 years or older among women who had 
prior hysterectomies, and was assigned a score of M=3, whereas premenopausal status scores 
were assigned as M=1. Serum CA 125 values were entered directly into the equation. Of note, the 
present study was conducted during a period in which the RMI was not used in routine clinical 
work-up, and was therefore calculated retrospectively from the registered parameters. This 
allowed a comparison of the results of clinical practice with a hypothetical situation in which the 
RMI would have been included in clinical management.
The decision to perform frozen section analysis was made by the surgeon on the basis of the 
suspicion of ovarian malignancy before or during surgery. The complete ovary or the ovarian 
cyst was sent fresh to the on-site laboratory of the Department of Pathology, to a centralized 
pathology department in another hospital, or was analysed on-site in an adapted setting during 
surgery by a pathologist from a centralised pathology department. The most suspicious parts 
of the tumour were selected for frozen section analysis. Final diagnosis of the tumour was 
based on full histopathologic examination of all surgical specimens removed. The pathologist 
who examined the paraffin slides was not masked to the frozen section diagnosis. Histology 
results from both frozen section analysis and paraffin (final) diagnosis were expressed as 
benign, borderline, or malignant. Borderline malignancies were allocated to the benign group 
for calculation of diagnostic performance of frozen section analysis. A total of six pathology 
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units covered the pathology activities of the 11 hospitals that participated in this study. One of 
these units covered four hospitals, two units covered two hospitals, and three units covered one 
hospital.
To evaluate the significance of the RMI in the decision to perform frozen section analysis, frozen 
section rates for benign, borderline, and malignant ovarian tumours (i.e. final histopathologic 
diagnosis) were calculated for various categories of RMI values. Descriptive statistics were 
performed to describe and present the data quantitatively. SPSS 16.0.1 for Windows (SPSS Inc., 
Chicago, IL, USA) was used for all statistical analyses.
RESULTS
A total of 724 women underwent surgery for an adnexal mass during the study period. One 
hospital (out of the 11 participating hospitals) only had two registered patients and was therefore 
excluded from further analyses. For 52 (7.2%) women, frozen section analysis was not performed 
because of clear evidence of malignancy before or during the surgical procedure, and these 
women were therefore excluded from the study. Of the remaining 670 women, 531 (79.3%) had 
benign conditions as the final histopathologic diagnosis, 70 (10.4%) had borderline tumours, and 
69 (10.3%) had malignant disease. Median age was 54 years (range 13–93) and 390 (58.2%) were 
postmenopausal. Median serum CA 125 was 20 U/mL (range 2–2914).
Frozen sections were performed in 323 (48.2%) patients, most of whom were diagnosed 
with benign ovarian tumours (Table 1). Among 169 mucinous tumours, frozen sections were 
performed for 105 (62.1%). By contrast, among all 501 other histologic types, frozen sections 
were performed for 218 (43.5%). When frozen sections were performed, 58 (93.5%) of 62 patients 
with ovarian cancer were properly staged, compared with 6 (85.7%) of 7 for whom no frozen 
sections were performed.
Table 2 presents the results of frozen section analysis compared with the final histopathologic 
diagnosis. The sensitivity, specificity, and positive and negative predictive values of frozen section 
analysis were 85.2% (95% confidence interval [CI] 74.7%–93.3%), 98.8% (95% CI 97.8%–100%), 
94.5% (95% CI 89.1%–100%), and 96.7% (95% CI, 93.6%–98.4%), respectively, for malignant 
tumours. The accuracy was 96.2% (95% CI, 93.8%–98.2%).
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Table 1. Final histopathologic classification and use of frozen section analysis in ovarian lesions.
 
Final histopathology
Total
(N=670)
Frozen sections 
performed
(n=323)
No frozen sections 
performed
(n=347)
Benigna 
Mucinous cystadenomas
Serous cystadenomas
Cystadenomas NOS
Endometriotic cysts
Dermoids
Fibroma 
531/670 (79.3)
124/531 (23.4)
92/531 (17.3)
146/531 (27.5)
57/531 (10.7)
56/531 (10.5)
56/531 (10.5)
206/323 (63.8)
69/206 (33.5)
32/206 (15.5)
41/206 (19.9)
16/206 (7.8)
14/206 (6.8)
34/206 (16.5)
325/347 (93.7)
55/325 (16.9)
60/325 (18.5)
105/325 (32.3)
41/325 (12.6)
42/325 (12.9)
22/325 (6.8)
Borderline 
Mucinous borderlines
Serous borderlines
Borderline NOS
70/670 (10.4)
37/70 (52.9)
28/70 (40.0)
5/70 (7.1)
55/323 (17.0)
29/55 (52.7)
21/55 (38.2)
5/55 (9.1)
15/347 (4.3)
8/15 (53.3)
7/15 (46.7)
0
Malignant 
Serous adenocarcinomas
Mucinous adenocarcinomas
Endometrioid adenocarcinomas
Clear cell carcinomas
Other malignancies
69/670 (10.3)
29/69 (42.0)
8/69 (11.6)
12/69 (17.4)
12/69 (17.4)
8/69 (11.6)
62/323 (19.2)
25/62 (40.3)
7/62 (11.3)
12/62 (19.4)
11/62 (17.7)
7/62 (11.3)
7/347 (2.0)
4/7 (57.1)
1/7 (14.3)
0
1/7 (14.3)
1/7 (14.3)
NOS, not otherwise specified.
Values are given as number/total number (percentage). 
aDiagnosis is based on the final histopathologic examination of all surgical specimens removed.
Table 2. Final histopathologic diagnosis by frozen section analysis among women with ovarian lesions.
Final histopathologic 
diagnosis Malignant Borderline Benign
Malignant (n=61)
Borderline (n=54)
Benign (n=206)
Total (n=321)
52 (85.2)
2 (3.7)
1 (0.5)
55 (17.1)
7 (11.5)
42 (77.8)
7 (3.4)
56 (17.4)
2 (3.3)
10 (18.5)
198 (96.1)
210 (65.4)
Values are given as number (percentage).
In two cases, frozen section analysis was undecided.
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Women with an RMI value below 20 were mostly diagnosed with benign disease on final 
histopathology (Table 3). Few women with an RMI value below 20 had frozen sections performed. 
Among 326 women with an RMI value between 20 and 100, 127 (39.0%) had frozen sections 
performed, of which 14 (11.0%) showed malignancies on final histopathology. Four (1.2%) women 
with an RMI value between 20 and 100 had malignant disease, and did not have frozen sections 
performed. Histopathologic types included one clear cell carcinoma, one serous adenocarcinoma, 
one mucinous adenocarcinoma, and one metastasised thyroid cancer. A total of 88 (13.1%) 
women had a RMI value between 100 and 200. Frozen sections were performed for 50 (56.8%) of 
these women, of which 3 (6.0%) showed malignant disease on final histopathology. Two (2.3%) 
women with an RMI value between 100 and 200 did not have frozen sections performed and 
were diagnosed with ovarian cancer (one serous adenocarcinoma and one adenocarcinoma not 
otherwise specified) on final histopathology. Among 147 women with a RMI value of more than 
200, most had frozen sections performed and 45 (34.1%) showed malignant disease on final 
histopathology (Table 3).
The 7 (1.0%) patients with ovarian cancer who did not have frozen section analysis were operated 
by general gynaecologists and, except for one patient, all required a second surgery for proper 
staging. In these cases, the surgeon was not initially aware of the presence of malignancy and 
therefore did not perform a proper staging procedure. Five of these missed ovarian cancers were 
in postmenopausal women.
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Table 3. RMI, menopausal status, and final histopathologic classification among women with and without 
frozen section analysis performed.
RMI and final 
histopathology
Total  
(N=670)
Frozen sections 
performed
(n=323)
No frozen sections 
performed
(n=347)
RMI <20
Premenopausal
Benigna
Borderline
Malignant
Postmenopausal
Benign
Borderline
Malignant
109 (16.3)
83 (76.1)
81 (97.6)
2 (2.4)
0
26 (23.9)
25 (96.2)
1 (3.8)
0
14 (12.8)
11 (78.6)
10 (90.9)
1 (9.1)
0
3 (21.4)
3 (100)
0
0
95 (87.2)
72 (75.8)
71 (98.6)
1 (1.4)
0
23 (24.2)
22 (95.7)
1 (4,3)
0
RMI 20 – 60
Premenopausal
Benign
Borderline
Malignant
Postmenopausal
Benign
Borderline
Malignant
226 (33.7)
89 (39.4)
76 (85.4)
10 (11.2)
3 (3.4)
137 (60.6)
123 (89.8)
10 (7.3)
4 (2.9)
78 (34.5)
27 (34.6)
18 (66.7)
7 (25.9)
2 (7.4)
51 (65.4)
41 (80.4)
7 (13.7)
3 (5.9)
148 (65.5)
62 (41.9)
58 (93.6)
3 (4.8)
1 (1.6)
86 (58.1)
82 (95.3)
3 (3.5)
1 (1.2)
RMI 60 – 100
Premenopausal
Benign
Borderline
Malignant
Postmenopausal
Benign
Borderline
Malignant
100 (14.9)
34 (34.0)
24 (70.6)
4 (11.8)
6 (17.6)
66 (66.0)
53 (80.3)
8 (12.1)
5 (7.6)
49 (49.0)
18 (36.7)
11 (61.1)
2 (11.1)
5 (27.8)
31 (63.3)
22 (71.0)
5 (16.1)
4 (12.9)
51 (51.0)
16 (31.4)
13 (81.3)
2 (12.4)
1 (6.3)
35 (68.6)
31 (88.6)
3 (8.5)
1 (2.9)
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RMI and final 
histopathology
Total  
(N=670)
Frozen sections 
performed
(n=323)
No frozen sections 
performed
(n=347)
RMI 100 – 140
Premenopausal
Benign
Borderline
Malignant
Postmenopausal
Benign
Borderline
Malignant
47 (7.0)
18 (38.3)
16 (88.9)
0
2 (11.1)
29 (61.7)
24 (82.8)
4 (13.8)
1 (3.4)
25 (53.2)
8 (32.0)
6 (75.0)
0
2 (25.0)
17 (68.0)
13 (76.5)
4 (23.5)
0
22 (46.8)
10 (45.5)
10 (100)
0
0
12 (54.5)
11 (91.7)
0
1 (8.3)
RMI 140 – 200
Premenopausal
Benign
Borderline
Malignant
Postmenopausal
Benign
Borderline
Malignant
41 (6.1)
11 (26.8)
7 (63.6)
3 (27.3)
1 (9.1)
30 (73.2)
24 (80.0)
5 (16.7)
1 (3.3)
25 (61.0)
5 (20.0)
2 (40.0)
2 (40.0)
1 (20.0)
20 (80.0)
15 (75.0)
5 (25.0)
0
16 (39.0)
6 (37.5)
5 (83.3)
1 (16.7)
0
10 (62.5)
9 (90.0)
0
1 (10.0)
RMI ≥200
Premenopausal
Benign
Borderline
Malignant
Postmenopausal
Benign
Borderline
Malignant
147 (21.9)
45 (30.6)
30 (66.7)
5 (11.1)
10 (22.2)
102 (69.4)
48 (47.1)
18 (17.6)
36 (35.3)
132 (89.8)
37 (28.0)
22 (59.5)
5 (13.5)
10 (27.0)
95 (72.0)
43 (45.3)
17 (17.9)
35 (36.8)
15 (10.2)
8 (53.3)
8 (100)
0
0
7 (46.7)
5 (71.4)
1 (14.3)
1 (14.3)
RMI, Risk of Malignancy Index. 
Values are given as number (percentage).
aDiagnosis is based on the final histopathologic examination of all surgical specimens removed.
Table 3. Continued
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DISCUSSION
The present results indicate that women with a RMI value below 20 have a low risk of malignancy 
and therefore do not require frozen sections to be performed. If a RMI cut-off value of 100 had 
been used in combination with postmenopausal status, three of the women in the present cohort 
who did not undergo frozen section analysis would have been diagnosed with malignancies at the 
time of primary surgery. On the basis of these results, it is recommended that postmenopausal 
women with a RMI value over 100 should be referred to centre hospitals where frozen sections 
can be performed and where proper facilities and expertise are available to perform the staging 
procedures if necessary.
Although frozen section analysis is a useful and reliable method to determine the nature of 
ovarian tumours,11-13 its inherent disadvantage is the extension of the total operating time and 
therewith the duration of anaesthesia. This is especially problematic in hospitals without on-
site pathology units, where frozen section analysis might be time-consuming and expensive as 
a result of the transport of the specimen to centralised pathology departments. In the present 
study, approximately 13% of patients with an RMI value below 20 had frozen sections performed, 
which could have been circumvented by applying an RMI cut-off to avoid superfluous frozen 
section testing in benign diseases.
Notably, the RMI used in the present investigation was as developed by Tingulstad et al.22 rather 
than the first version developed by Jacobs et al.,1 because the latter used an ultrasonography 
score (U) of 0 when none of the ultrasonography features were present, thus resulting in a RMI of 
0 irrespective of the CA 125 level. Nevertheless, CA 125 level is considered an important variable 
in the RMI and was therefore included in the present study as suggested by Tingulstad et al.22
Among premenopausal patients, the diagnostic accuracy of serum CA 125 is expected to be 
lower. Endometriosis, which is frequently diagnosed in premenopausal women, is known 
to cause elevated CA 125 values.23 In the present study population, approximately 42% of 
women were premenopausal, 17% of whom were diagnosed with endometriotic lesions on 
final histopathology. Median serum CA 125 in this subgroup was 80 U/mL (range 8–868). Of 
women with endometriotic lesions, 14 (29.2%) had RMI values over 200 and 9 (64.3%) of these 
underwent frozen section analysis, indicating that women with endometriotic lesions require 
special attention, as previously emphasized by Daponte et al.24
The RMI was previously found to have a sensitivity of 81% and a specificity of 85% for 
discrimination between benign and malignant ovarian tumours at a cut-off value of 200.19 In the 
present study, a total of 523 patients had a RMI value below 200, of whom 23 (4.4%) had a final 
diagnosis of ovarian cancer; however, on the basis of RMI alone, these patients would probably 
have been classified as having benign disease, with likely consequences with regard to the extent 
of surgery. This clearly illustrates the shortcomings of the RMI.
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A limitation of the present study is its retrospective nature. Nevertheless, this characteristic does 
not have an impact on the reliability of the calculated RMI. Because the gynaecologists were 
asked to register the variables of the RMI preoperatively, the RMI could be reliably calculated 
postoperatively. Furthermore, all CA 125 assays were performed at all participating centres 
as part of routine preoperative assessment. Thus, despite the use of different CA 125 assays 
reflecting clinical practice, this could be a limitation of the study design.
Although the RMI already includes menopausal status, the present results justify the combination 
of the RMI with menopausal status to further improve the care of women with ovarian tumours. 
Indeed, the results suggest that a RMI cut-off value of 100 can be used in combination with a 
postmenopausal status to select patients in whom frozen sections should be performed. If this rule 
had been applied in the present study population, 29 additional frozen sections would have been 
performed to diagnose three further patients with malignancies at the time of primary surgery, 
which is considered an acceptable rate of extra diagnostic work-up. Further prospective research 
is recommended to determine whether an RMI cut-off value of 100 should be implemented in the 
clinical management of postmenopausal women with adnexal masses.
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ABSTRACT
Introduction
The objective was to determine diagnostic accuracy and interobserver agreement of laparoscopic 
examinations of ovarian tumours, using videotaped laparoscopic procedures.
Material and methods
Retrospective observational study, conducted in the Radboud university medical center, 
Nijmegen and Máxima Medical Center, Veldhoven, the Netherlands. 10 gynaecologists scored 
video recordings of laparoscopic examinations of ovarian tumours. Scoring was performed with 
and without depriving of clinical information. Parameters included: adnex normal/abnormal, 
presence of adhesions, smooth surface, abnormal vessels, endometriosis, metastases, and 
free fluid. Clinical impression was classified as (probably) benign or (probably) malignant, and 
a specific diagnosis was asked for. Borderline tumours were included in the malignant group. 
Kappa (κ) statistics were used to determine the level of agreement between observers. 
Results
41 women were included. Histological diagnoses included 36 (88%) benign, two (5%) borderline, 
and three (7%) malignant tumours. Scored without clinical information, overall sensitivity of 
diagnosis of malignancy was 49%, specificity was 95%. With clinical information provided, 
outcomes were 61% and 94%, respectively. Interobserver agreement of diagnosis of malignancy 
was moderate and fair in both groups of observers (κ=0.51 and 0.26, respectively). Agreement 
was best for adhesions and endometriosis (κ=0.71 and 0.60). Agreement for other parameters 
was poor to fair (κ=-0.02–0.34). 
Conclusions
Diagnostic performance of evaluations of videotaped laparoscopic examination of ovarian 
tumours was evaluated, sensitivities of diagnosis of malignancy were 49-61%. Interobserver 
agreement of overall clinical impression and most diagnostic features of ovarian tumours were 
unsatisfactory and therefore not useful for clinical practice yet. 
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INTRODUCTION
Laparoscopy is a common approach for the surgical removal of (presumably benign) ovarian 
tumours. Advantages of laparoscopic gynaecologic surgery over laparotomy are: less post-
operative pain, less postoperative complications, better cosmetic results, and a shorter length 
of hospital stay.1 Minimally invasive surgery has been shown to be safe and effective in the 
management of uterine and cervical cancer, and is now a common procedure in these malig-
nancies. Laparoscopy in women with ovarian cancer is however associated with an increased rate 
of intraperitoneal spillage. This may lead to dissemination of tumour cells, an upgrade in tumour 
stage, and subsequently a risk of chemotherapy needed.2 An additional concern is the risk of 
laparoscopic port-site metastases.3 Nonetheless, a review of the literature on the role of minimally 
invasive surgery in staging of ovarian cancer,4 and a recent retrospective study5 have concluded 
that women with borderline ovarian tumours and apparent early stage ovarian malignancies can 
safely and effectively undergo laparoscopic surgical management, when performed in referral 
centres by trained gynaecologic oncologists. 
When an ovarian tumour is detected, it is meaningful to establish whether it is likely to be 
malignant or benign as this diagnosis will guide decision making on the surgical approach. 
A number of tools are available to facilitate preoperative diagnosis, such as ultrasonography, 
tumour markers and prediction models on the risk of malignancy. The Risk of Malignancy Index 
(RMI), introduced by Jacobs et al.6 in 1990, was the first simple diagnostic index suitable for use 
in clinical practice, which defines the optimal combination of ultrasound features, menopausal 
status, and CA 125 value. In a previous publication,7 we confirmed an RMI cut-off level of 200 for 
discrimination between benign and malignant ovarian tumours, which showed a sensitivity of 
81% and a specificity of 85%. Several other diagnostic models have been developed since the 
introduction of the RMI, and some of them performed better, as found in a recent systematic 
review and meta-analysis.8 Recent studies suggest the International Ovarian Tumour Analysis 
Logistic Regression model LR2 or the Simples Rules as the approach of choice when expert 
ultrasound expertise is not available. Also, several studies have concluded that these approaches 
maintain their performances in the hands of relatively inexperienced examiners.9-12
Due to the heterogeneity of ovarian tumours, the preoperative diagnosis is limited and presence 
of malignancy cannot be determined with 100% accuracy until histological examination of 
the surgical specimens. Therefore intraoperative interpretation of ovarian tumours is useful, 
and has hardly been studied so far. There are also no standardised protocols for laparoscopic 
interpretation of ovarian tumours (benign, borderline, or malignant). The aim of the present 
study was to determine the overall diagnostic accuracy and the interobserver agreement 
of laparoscopic examinations of ovarian tumours with a scoring system, using videotaped 
laparoscopic procedures.
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MATERIAL AND METHODS
This retrospective observational study was conducted in the Radboud university medical center, 
Nijmegen and Máxima Medical Center, Veldhoven. The study was approved by the medical 
ethics committee of the Radboud university medical center. Video recordings of laparoscopic 
examinations of ovarian tumours were assessed independently by 10 observers, including 
six gynaecologic oncologists, three general gynaecologists, and one fellow in gynaecologic 
oncology. All observers were experienced laparoscopic surgeons (>100 adnexal laparoscopic 
surgeries). To simulate clinical practice, specific training with the scoring system before initiation 
of the study was not performed. Patient information and identification data were removed from 
each recording prior to scoring to protect patient identity. Eight observers were deprived of 
clinical information. After initial scoring, six observers were provided with clinical information 
in a next step and had the opportunity to change their suggested diagnoses. The remaining two 
observers scored once, with the clinical information provided directly. All observers scored the 
video recordings independently and separately. 
Laparoscopic examination was performed as part of routine clinical practice in women with 
ovarian tumours. The included patients were operated between February 2009 till February 
2012. Inclusion was not consecutive regarding patients with laparoscopy for ovarian tumours, but 
depended on the availability of video recordings. Consecutive patients with available video re-
cordings were included. The procedure of scoring was standardised and each adnex was scored 
on a case record form. A case record form was produced for purpose of the study, since no scoring 
systems were reported in literature. The parameters included: adnex normal/abnormal, presence 
of adhesions, smooth surface, abnormal vessels, endometriosis, metastases, and free fluid. The 
observers were asked to classify the tumours as benign, probably benign, probably malignant, 
or malignant. A specific diagnosis was asked for, using the following categories: cystadenoma; 
endometriotic cyst; dermoid cyst; follicular cyst or theca lutein cyst; borderline malignancy; 
ovarian carcinoma; and other. Video recordings were excluded if five of more observers judged 
them not suitable to score. The final diagnosis of the ovarian tumours was based on the full histo-
pathologic examination of all surgical specimens removed and was considered the gold standard.
The overall diagnostic accuracy of the videotaped observing based diagnosis was analyzed in 
relation to the presence or absence of a malignancy, in terms of sensitivity and specificity. 
Kappa (κ) statistics (Fleiss’ multirater κ) with their 95% confidence intervals were used to 
determine the level of agreement between observers. Agreement was tested both by the overall 
diagnosis (benign versus malignant) and by the individual diagnostic features of the tumours. 
When κ equals one, perfect agreement is implied; whereas when κ equals zero, the agreement 
is no better than that which would be obtained by chance. Kappa values under 0.20 were 
considered poor; 0.21–0.40 fair; 0.41–0.60 moderate; 0.61–0.80 good; and 0.81–1.00 excellent. 
We used SPSS 20.0.0.1 for Windows for all statistical analyses.
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RESULTS
Video recordings were scored of 41 patients. The median age of the women was 41 years (range 
24–69 years); the majority of women (n=29, 71%) were premenopausal. The histologic diagnoses 
(based on final histopathologic examination) are noted in Table 1 and included 36 (88%) benign, 
two (5%) borderline, and three (7%) malignant tumours.
Most suggested diagnoses, based on the video recordings, were cystadenoma and endometriotic 
cysts (63% of all diagnoses). Intra-abdominal metastases were only observed in a few patients 
by three observers (observer2: n=3; observer5: n=1; observer8: n=1). These observations were 
incorrect as these cases were classified as benign on final histopathologic examination.
The two serous borderline cases were mostly scored as benign, based on the video recordings. 
They were diagnosed mainly as cystadenoma (one case by five, the other by four observers). The 
two serous adenocarcinomas were correctly diagnosed by all observers except two, who each 
scored one case as not evaluable. The metastasised galbladdercarcinoma was misdiagnosed by 
all observers. This case was mostly scored as cystadenoma (six observers), and two observers 
scored this case as borderline malignant.
Table 1. Histological diagnoses of the 41 patients included in the study.
 
Histological diagnosisA
 
n
Correctly scored by 
observers (overall, %)
 
Range (%)
Benign
Endometriotic cyst
Dermoid
Simple cyst
Serous cystadenomaB
Mucinous cystadenomaB
Fibroma
15
5
6
5
2
3
77
26
47
51
7
(47-100)
(0-40)
(33-67)
(29-86)
(0-33)
Borderline
Serous borderline 2 20 (0-50)
Malignant
Serous cystadenocarcinoma
Gallbladder carcinoma
2
1
70
0
(0-100)
(0-0)
A Diagnosis is based on the final histopathologic examination of surgical specimens removed.
B Observers scored ‘cystadenoma’, no further differentiation was asked for.
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The observers who were deprived of clinical information and got the opportunity to change their 
suggested diagnosis after clinical information was provided, stayed with their first suggestion in 
most (borderline) malignant cases (87%). Two observers correctly diagnosed the borderline cases 
only after clinical information was provided. One observer scored a borderline case as ovarian 
carcinoma first and then changed it to endometriosis when provided with clinical information.
Of all benign cases (n=36), 6 (17%) were diagnosed as borderline or malignant, based on the 
video recordings. These included two endometriotic cysts, two dermoids, one simple cyst and 
one serous cystadenoma. As to the benign cases, the observers who were deprived of clinical 
information and got the opportunity to change their suggested diagnosis after clinical information 
was provided, changed their diagnoses in three cases correctly, and in two cases incorrectly.
Overall sensitivity of diagnosis of malignancy was 49% in observers deprived of clinical information, 
with a specificity of 95%. Once clinical information was provided the sensitivity and specificity 
were 61% and 94%, respectively (Table 2). The gynaecologist’s subspecialty (gynaecologic 
oncologist or general gynaecologist) was not related to the accuracy of assessments.
Table 3 presents the interobserver agreements of scored items. The interobserver agreement of 
diagnosis of malignancy was moderate in observers deprived of clinical information (κ=0.51) and 
fair in observers provided with clinical information (κ=0.26). Agreement was best for adhesions 
and endometriosis (κ=0.71 and 0.60). Agreement for the other parameters was poor to fair (κ= 
-0.02–0.34).
Table 4 presents the frequencies of observed variables in benign and malignant cases by all 10 
observers. Smooth surface, adhesions and endometriosis were more frequently observed in 
benign cases. Numbers were too small to perform statistical analyses.
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Table 2a. Overall sensitivity and specificity of the videotaped observing based diagnosis of malignancy, 
observers deprived of clinical information.
Observer n Sensitivity (%) Specificity (%)
1 39 60 94
2 40 25 94
3 41 80 94
4 41 40 94
5 40 60 91
6 39 40 100
7 41 40 100
8 38 40 94
Overall 40 49 95
n refers to the number of evaluable cases. 
Observers 2, 3, 4, 5, 6 and 7 are gynaecologic oncologists.
Table 2b. Overall sensitivity and specificity of the videotaped observing based diagnosis of malignancy, 
observers provided with clinical information.
Observer n Sensitivity (%) Specificity (%)
1
2
3
4
5
6
9
10
Overall
41
30
41
41
40
41
40
40
39
60
100
60
40
60
60
60
60
61
94
93
100
92
89
100
94
91
94
n refers to the number of evaluable cases. 
Observers 2, 3, 4, 5 and 6 are gynaecologic oncologists.
84
Chapter 6
Table 3a. Interobserver agreement of specific features of the videotaped laparoscopic evaluations of ovarian 
tumours, observers deprived of clinical information.
Variable Agreement (%) KappaD 95% CIE
Adhesions
Smooth surface
Abnormal vessels on surface
Endometriosis
Intra-abdominal metastasesA
Free fluidA
Clinical impressionB
Specific diagnosisC
86
83
66
80
96
70
93
27
0.71
0.22
0.31
0.60
-0.02
0.34
0.51
-0.01
0.65-0.78
0.15-0.28
0.24-0.37
0.53-0.67
-0.10-0.05
0.26-0.43
0.44-0.57
0.04-0.04
A Scored per patient, not per adnex.
B (probably) benign versus (probably) malignant.
C Categories: cystadenoma; endometriotic cyst; dermoid cyst; follicular cyst or theca lutein cyst; borderline 
malignancy; ovarian carcinoma; and other.
D Fleiss’ multirater kappa
E 95% confidence interval
Table 3b. Interobserver agreement of specific features of the videotaped laparoscopic evaluations of ovarian 
tumours observers provided with clinical information. 
Variable Agreement (%) KappaD 95% CIE
Adhesions
Smooth surface
Abnormal vessels on surface
Endometriosis
Intra-abdominal metastasesA
Free fluidA
Clinical impressionB
Specific diagnosisC
78
87
73
87
100*
68
82
-15
0.52
0.42
0.22
0.72
0.72
0.19
0.26
-0.45
0.21-0.83
0.13-0.72
-0.07-0.52
0.43-1.00
0.43-1.00
-0.13-0.50
-0.05-0.57
-0.56-0.35
A Scored per patient, not per adnex.
B (probably) benign versus (probably) malignant.
C Categories: cystadenoma; endometriotic cyst; dermoid cyst; follicular cyst or theca lutein cyst; borderline 
malignancy; ovarian carcinoma; and other.
D Fleiss’ multirater kappa.
E 95% confidence interval.
*all observers scored ‘no’ in all cases.
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Table 4a. Frequencies of observed variables in benign and malignant cases by observers deprived of clinical 
information.
Variable
BenignA n=36
Overall observed (%)
MalignantA n=5
Overall observed (%)
Adhesions
Smooth surface
Abnormal vessels on surface
Endometriosis
Intra-abdominal metastases
Free fluid
44
89
50
38
2
25
36
64
55
2
0
50
n refers to the number of patients.
A Diagnosis is based on the final histopathologic examination of surgical specimens removed.
Table 4b. Frequencies of observed variables in benign and malignant cases by observers provided with clinical 
information.
 
Variable
BenignA n=36
Overall observed (%)
MalignantA n=5
Overall observed (%)
Adhesions
Smooth surface
Abnormal vessels on surface
Endometriosis
Intra-abdominal metastases
Free fluid
36
91
20
43
2
24
21
63
33
0
0
50
n refers to the number of patients.
A Diagnosis is based on the final histopathologic examination of surgical specimens removed.
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DISCUSSION
This study assessed the diagnostic performance of a standardised laparoscopic scoring system, 
in order to explore whether implementation might improve the quality level of laparoscopic 
examination of ovarian tumours. To our knowledge this is the first study reporting a method for 
assessing the quality of laparoscopic examination of ovarian tumours. 
Borderline tumours were allocated to the malignant group for the purpose of this study, given the 
high conversion rate from borderline to malignant on the final histology report.13 A classification 
of borderline ovarian tumours as benign lesions would also have been justifiable. Borderline 
ovarian tumours tend to occur in younger women and they are usually associated with a good 
long-term prognosis.14 Therefore, more conservative, fertility-sparing surgery should be carried 
out on women who are of reproductive age and who have not completed their families. With 
respect to the present study, the sensitivity of the diagnosis of malignancy would be higher in 
case borderline tumours had been allocated to the benign group. 
One patient was diagnosed with a metastasis of gallbladder carcinoma in an ovary on final 
histopathology. Preoperative diagnosis was benign, ultrasound showed one enlarged multilocular 
ovary of nine cm, the other ovary contained solid parts and measured four cm. The patient was 
postmenopausal and the preoperative serum CA 125 level was 55 units/mL. We did not exclude 
this case, because the occurrence of secondary malignancies reflects clinical practice and should 
always be considered to avoid pitfalls in diagnosis and therapy. 
The strengths of our study include the number of observers as well as the different subspecialties 
of the observers. The fact that we used video recordings of laparoscopic examinations may 
be considered both a strength and a weakness. It may be considered a strength, because the 
observers were exposed to exactly the same information, and their assessments were not biased 
by any clinical information. Another benefit of using video recordings is that we did not have to 
interfere with clinical practice for this observational study. 
On the other hand, the use of video recordings may be considered a weakness, because the 
reproducibility of live laparoscopic examinations might be superior to that of evaluation of 
video recordings and these results therefore cannot be extrapolated to live examinations. The 
use of video recordings may not reflect conditions during standard laparoscopic examination 
of that observer. This could have caused the observers to depart from their usual examination 
techniques, resulting in inaccuracies in the assessment of different diagnostic features. Providing 
clinical information (age, menopausal status, laboratory results, findings on ultrasound) did 
enhance the interpretation of the video recordings in our study, although not drastically. Another 
weakness is the method of including patients. We depended on the availability of video recordings 
of laparoscopic procedures and therefore patient inclusion was not consecutive. In future studies, 
women should be included consecutively for a representative sample of study patients.
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Similar studies which have used video recordings include laparoscopic reproducibility studies 
on the diagnosis of endometriosis, and showed a high degree of variability in reproducibility. 
Weijenborg et al.15 assessed the intraobserver and interobserver reliability of videotaped 
laparoscopic evaluations for endometriosis and adhesions. The authors concluded that the 
evaluations of videotaped laparoscopies for endometriosis were reliable and justified the use 
of video recordings. However, in women with endometriosis, observers tended to disagree on 
the severity and extent of the endometriotic disease. The authors have shown that, regarding 
adhesions, evaluation during videotaped laparoscopy was not reliable. In our study, the 
interobserver agreement for presence of adhesions was good (κ=0.71) for observers deprived 
of clinical information, however adhesions were observed not only in malignant cases (36%) but 
also in benign cases (44%). Once clinical information was added, interobserver agreement for 
presence of adhesions was moderate (κ=0.52), and adhesions were observed in 21% of malignant 
and 36% of benign cases. This does not support the use of presence of adhesions as a reliable sign 
of malignancy. 
Buchweitz et al.16 also evaluated video recordings of laparoscopic examinations of endometriotic 
diseases, and found a considerable interobserver variability. A study by Bowman et al.17 compared 
scorings of adnexal adhesions during real-time laparoscopy with assessments of videotaped 
laparoscopies in women who had been diagnosed previously with adhesions. The authors found 
a large variation in adhesion scorings and a poor level of agreement on subdivisions of adhesion 
total scores. 
Poor to fair interobserver agreement suggests that laparoscopic examination of ovarian tumours 
would need further evaluation before clinical implementation. Intraoperative histopathologic 
diagnosis by for example frozen section analysis is obviously still considered necessary and care 
should be taken to avoid tumour spillage with all adnexal masses. Another implication of poor to 
fair agreement is that the diagnostic feature warrants attempts to better define its categories. In 
case better definitions would not result in increased agreement, the feature should not be used 
as a reliable sign of disease. 
In conclusion, this study evaluated diagnostic performance of evaluations of videotaped 
laparoscopic examination of ovarian tumours. Sensitivities of diagnosis of malignancy were low. 
The interobserver agreement of the overall clinical impression and most diagnostic features 
of ovarian tumours used in this study were unsatisfactory and therefore not useful for clinical 
practice.
CONFLICTS OF INTEREST STATEMENT
The authors do not report any potential conflicts of interest.
88
Chapter 6
REFERENCES
1. Medeiros LR, Rosa DD, Bozzetti MC, Fachel JM, Furness S, Garry R, et al. Laparoscopy versus 
laparotomy for benign ovarian tumour. Cochrane Database Syst Rev 2009:CD004751.
2.	 Gal	D,	Lind	L,	Lovecchio	JL,	Kohn	N.	Comparative	study	of	laparoscopy	vs.	laparotomy	for	adnexal	
surgery:	efficacy,	safety,	and	cyst	rupture.	J	Gynecol	Surg	1995;11:153-8.
3. Ramirez PT, Frumovitz M, Wolf JK, Levenback C. Laparoscopic port-site metastases in patients with 
gynecological malignancies. Int J Gynecol Cancer 2004;14:1070-7.
4. Iglesias DA, Ramirez PT. Role of minimally invasive surgery in staging of ovarian cancer. Curr Treat 
Options Oncol 2011;12:217-29.
5. Gallotta V, Ghezzi F, Vizza E, Chiantera V, Ceccaroni M, Franchi M, et al. Laparoscopic staging of 
apparent early stage ovarian cancer: results of a large, retrospective, multi-institutional series. 
Gynecol Oncol 2014;135:428-34.
6.	 Jacobs	 I,	 Oram	 D,	 Fairbanks	 J,	 Turner	 J,	 Frost	 C,	 Grudzinskas	 JG.	 A	 risk	 of	 malignancy	 index	
incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis 
of ovarian cancer. Br J Obstet Gynaecol 1990;97:922-9.
7. van den Akker PA, Aalders AL, Snijders MP, Kluivers KB, Samlal RA, Vollebergh JH, et al. Evaluation 
of	the	Risk	of	Malignancy	Index	in	daily	clinical	management	of	adnexal	masses.	Gynecol	Oncol	
2010;116:384-8.
8. Kaijser J, Sayasneh A, van Hoorde K, Ghaem-Maghami S, Bourne T, Timmerman D, et al. Presurgical 
diagnosis	 of	 adnexal	 tumours	 using	mathematical	 models	 and	 scoring	 systems:	 a	 systematic	
review and meta-analysis. Hum Reprod Update 2014;20:449-62.
9. Nunes N, Yazbek J, Ambler G, Hoo W, Naftalin J, Jurkovic D. Prospective evaluation of the IOTA 
logistic regression model LR2 for the diagnosis of ovarian cancer. Ultrasound Obstet Gynecol 
2012;40:355-9.
10. Alcazar JL, Pascual MA, Olartecoechea B, Graupera B, Auba M, Ajossa S, et al. IOTA simple rules for 
discriminating	between	benign	and	malignant	adnexal	masses:	prospective	external	validation.	
Ultrasound Obstet Gynecol 2013;42:467-71.
11. Sayasneh A, Kaijser J, Preisler J, Johnson S, Stalder C, Husicka R, et al. A multicenter prospective 
external	 validation	 of	 the	 diagnostic	 performance	 of	 IOTA	 simple	 descriptors	 and	 rules	 to	
characterize ovarian masses. Gynecol Oncol 2013;130:140-6.
12.	 Sayasneh	A,	Wynants	L,	Preisler	J,	Kaijser	J,	Johnson	S,	Stalder	C,	et	al.	Multicentre	external	validation	
of IOTA prediction models and RMI by operators with varied training. Br J Cancer 2013;108: 
2448-54.
13. Cross PA, Naik R, Patel A, Nayar AG, Hemming JD, Williamson SL, et al. Intra-operative frozen 
section analysis for suspected early-stage ovarian cancer: 11 years of Gateshead Cancer Centre 
experience.	BJOG	2012;119:194-201.
14. Burger CW, Prinssen HM, Baak JP, Wagenaar N, Kenemans P. The management of borderline 
epithelial tumors of the ovary. Int J Gynecol Cancer 2000;10:181-97.
15. Weijenborg PT, ter Kuile MM, Jansen FW. Intraobserver and interobserver reliability of videotaped 
laparoscopy evaluations for endometriosis and adhesions. Fertil Steril 2007;87:373-80.
89
Prediction of ovarian histology by laparoscopic observation
6
16.	 Buchweitz	O,	Wulfing	P,	Malik	E.	 Interobserver	variability	 in	 the	diagnosis	of	minimal	and	mild	
endometriosis. Eur J Obstet Gynecol Reprod Biol 2005;122:213-7.
17. Bowman MC, Li TC, Cooke ID. Inter-observer variability at laparoscopic assessment of pelvic 
adhesions. Hum Reprod 1995;10:155-60.

Anne M. van Altena
Petronella A.J. van den Akker
Joanne A. de Hullu 
Petronella B. Ottevanger
Annet L. Aalders
Rene Gerritse 
Martin Happel 
Marcel P. Hoekstra
Mark-Jan Janssen
Rahul A.K. Samlal
Kirsten M.W.H. Smeets
Marc P.M.L. Snijders
Maria J. Vasmel
Jos H.A. Vollebergh
Lambertus A.L.M. Kiemeney
Leon F.A.G. Massuger 
Obstetrics and Gynecology 2013; 122(3):668-75 
Efficacy of a regional network 
for ovarian cancer care
92
Chapter 7
ABSTRACT
Objective
To study the influence of a regional collaboration in epithelial ovarian cancer care on staging pro-
cedures, debulking results, and survival.
Methods
In an effort to optimise epithelial ovarian cancer treatment, a regional collaboration was intro-
duced in the Netherlands in 2000. Gynaecologic oncologists from the university centre conducted 
surgery in community hospitals when ovarian cancer was considered based on the Risk of 
Malignancy Index or clinical suspicion. The National Cancer Registry registered 1,554 patients 
with epithelial ovarian cancer diagnosed in 11 participating Dutch hospitals between 1996 and 
2010. Surgical procedures were compared during three periods (1996–1999, 2000–2004, and 
2005–2009). Log-rank tests compared Kaplan-Meier survival curves of progression-free and 
overall survival before (1996–2000) and during the start of the collaboration (2001–2005).
Results
Staging was adequate for 139 patients (23.0%) before collaboration, and this proportion increased 
during the study periods to 32.1% and 62.1% (P<.01), when gynaecologic oncologists more often 
staged cancer in patients (36.7% compared with 54.7% and 80.6%; P<.01). For 1,197 patients with 
advanced stage disease (stage IIb or greater), the proportion of debulking procedures with an 
optimal (residual volume less than 1 cm) as well as a complete result (no residuals) increased 
during the 14-year study period from 57.4% to 76.5% (P<.01) and from 24.1% to 43.4% (P<.01), 
respectively. Survival rates were similar before and during the start of the collaboration. In 
multivariable analysis, the treatment variables completeness of debulking, chemotherapy, and 
gynaecologic oncologist attendance were independent prognostic factors for overall survival, as 
were age, stage, and tumour grade.
Conclusions
After regional collaboration, gynaecologic oncologists attended more surgeries and surgical 
outcomes improved, but progress in survival could not be demonstrated. Regional collaboration 
improved care for ovarian cancer patients.
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INTRODUCTION
Epithelial ovarian cancer is the most lethal gynaecological cancer in the developed world, and 
the prognosis has improved only slightly in recent decades. Changes in chemotherapy regimens 
achieved progress, but further improvement of survival may be expected from surgical treatment.
A meta-analysis showed that increased cytoreduction is associated with better survival.1 Com-
plete debulking gives the greatest benefit of surgery.2,3 A full staging procedure will upstage 
approximately 30% of the patients with early stage disease.4,5 It is generally accepted that 
gynaecologic oncologists perform the surgical procedures more adequately than general gynae-
cologists,6,7 which results in better survival.6,8-10 An overview of the European pattern of care 
in the 1990s showed that substantial numbers of patients with ovarian cancer were treated 
suboptimally.11 At that time in the Netherlands, general gynaecologists treated most patients in 
the hospital of diagnosis, and still do in many other countries. Initiatives to centralise treatment 
have been launched in the past 20 years.
Regional collaboration in gynaecologic oncology was introduced in 2000, and 11 hospitals par-
ticipated. The main goal was to improve care by means of consultations with gynaecologic 
oncologists when ovarian cancer was suspected. The 11 hospitals cover a region with 1.7 million 
inhabitants; approximately 110 patients have epithelial ovarian cancer diagnosed annually. The 
Risk of Malignancy Index (RMI) was implemented in 2005 to improve care with standardised risk 
assessment for pelvic masses.12
The aims of our population-based study were to assess changes that coincide with the introduction 
of the collaboration and to evaluate the role of the collaboration in care. The attendance of 
gynaecologic oncologists during surgery, staging and debulking results, and survival of patients 
are all factors that we compared before and after the regional network was introduced.
MATERIALS AND METHODS
The Institutional Board of the National Cancer Registry and all the gynaecologic departments 
involved gave their ethical approval for this retrospective population-based study in the east of 
the Netherlands. All consecutive patients in this region with epithelial ovarian cancer diagnosed 
between 1 January 1996 and 1 January 2010 were selected from the Netherlands Cancer Registry. 
This registry is based on the reports of all newly diagnosed malignancies in the automated 
nationwide pathology archive and the national registry of hospital discharge diagnoses. Trained 
medical registrars, using a standard case record form, studied the hospital records of the 
patients. We compared the surgical results of 1996–1999 (before the collaboration) with those 
of 2000–2004 (during introduction of the collaboration) and 2005–2009 (full introduction of the 
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collaboration). To allow sufficient follow-up, we studied survival during two calendar periods 
(1996–2000 and 2001–2005).
The 11 hospitals involved one specialised university centre hosting five gynaecologic oncologists. 
These gynaecologists completed a fellowship in gynaecologic oncology or are registered as 
gynaecologic oncologists by the Dutch Society of Obstetrics and Gynaecology (or both). The three 
teaching hospitals that were involved in the network had two semi-specialising gynaecologists 
and approximately eight general gynaecologists each. Semi-specialising gynaecologists are 
not formally trained in oncology, but they treat most of the oncology patients in the larger 
teaching hospitals. Seven nonteaching general hospitals with four to six general gynaecologists 
collaborated. The maximum radius from the university medical centre to the satellite hospitals 
was approximately 100 km.
From 2005 onward, gynaecologists were requested to register the RMI parameters for all patients 
with adnexal masses for the purpose of a prospective observational study of the effectiveness of 
the RMI.12 This index was calculated as the multiplied value of the ultrasound score, menopausal 
status, and serum CA 125 level, as Tingulstad proposed in 1999.13 In 2008, it was formally 
introduced as a tool for selecting patients for surgery performed by a gynaecologic oncologist. 
A score of 200 or more on the RMI indicated the need for a gynaecologic oncologist. If the score 
was less than 200, the gynaecologic oncologist only participated when specifically requested.
In agreement with previous studies, we defined the minimal adequate staging as a total abdo-
minal hysterectomy and bilateral salpingo-oophorectomy, infracolic omentectomy, at least one 
resected lymph node, and one peritoneal biopsy. As the evidence-based Dutch guideline 2009 
states,14 a staging procedure should include resection of at least 10 lymph nodes. We decided to 
show the results according to our definition as well as the number of lymph nodes. We defined 
optimal debulking as leaving no residual tumour larger than 1 cm in diameter. Complete debulking 
constitutes surgery with no macroscopic residual tumour. We analysed the debulking results for 
patients with advanced stage disease (stage IIb or higher).
We used the Pearson χ2 and Student t test to compare categorical and continuous characteristics. 
We used survival techniques to study the time to recurrence or to death. We defined progression-
free survival as the interval between the date of diagnosis and the date of tumour recurrence or 
the date of death, whichever occurred first.
Women with no recurrence were censored at their last follow-up date. We defined recurrence 
as a clinical examination or radiologic study with evidence of recurrent disease, preferably with 
pathologic confirmation or an increase of CA 125 greater than or equal to twice the upper normal 
limit on two occasions at least 1 week apart. We defined overall survival as the time between 
diagnosis and death or the last follow-up date. The women still living at the last follow-up date, 1 
January 2011, were censored.
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We calculated the Kaplan-Meier estimates of progression-free and overall survival in the time 
groups. We also calculated the survival figures for those patients who were treated by a gynae-
cologist (i.e., underwent a debulking surgery) because this group may primarily benefit from the 
collaboration. The log-rank test determined differences in Kaplan-Meier estimates.
Univariable proportional hazards models helped us study the influence of clinicopathologic 
factors on overall survival. We used a multivariable model to determine the effect of the study 
period on survival adjusted for other prognostic variables. All P values are two-sided, and we 
considered the associations significant at P<.05. We used the Statistical Package for Social 
Sciences version 16.0 for the analyses.
RESULTS
A total of 1,554 patients in the region had epithelial ovarian cancer diagnosed. Table 1 shows 
their clinicopathologic characteristics. Most of these patients had advanced stage of disease. No 
International Federation of Gynecology and Obstetrics stage was recorded in the medical records 
for 107 patients, and the pathology reports or surgical reports (or both) did not clarify the exact 
stage. Three of the patients were categorised as having early stage disease diagnosed and 98 
patients had advanced stage disease diagnosed. The stage remained unclear for six patients who 
were excluded from the analysis of surgical outcomes.
Table 1 shows the characteristics during the various study periods. During the last period, more 
serous cancers and fewer adenocarcinomas “not otherwise specified” were diagnosed. The grade 
was more often unknown in this last period. Patients more often received adequate platinum-
based chemotherapy over time (P=.04).
Only patients who needed staging surgery were included in the staging analysis. Staging was not 
applicable for 1,033 patients because an advanced stage became clear before or during surgery. 
A total of 362 patients underwent primary staging surgery, and another 91 patients underwent 
staging surgery secondarily, for example, when initially benign or borderline disease had been 
expected. The information was lacking for one patient.
The reasons for omitting a staging procedure were recorded in 68 medical records. The main 
reasons were fertility, another indication for chemotherapy (tumour histology), and poor 
condition. The proportions of omitted staging surgeries for the three calendar periods were 
somewhat similar: 15 (3.4%) for the first period; 29 (5.1%) for the second period; and 24 (4.4%) for 
the third period. A gynaecologic oncologist more frequently performed the surgery for patients 
with an RMI more than 200. Gynaecologic oncologists were involved in 33.9% of the surgeries 
during the first period, in 57.5% during the second period, and in 87.5% during the third period. 
Table 2 shows that gynaecologic oncologists performed increasingly more adequate staging 
procedures and surgeries during the 14-year study period.
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A total of 1,197 patients had disease that was International Federation of Gynecology and 
Obstetrics stage IIb or more, as clinically or surgically determined. Of these patients, 737 (61.6%) 
underwent primary debulking surgery. Clinical data for three patients were lacking. In 457 
women, the primary debulking surgery was cancelled. The decisions about debulking surgery 
were based on clinical signs, imaging studies, or the patient’s refusal. The decision also could 
be made soon after the surgery started, after inspection of the tumour alone. The main reasons 
for omitting primary debulking were the clinical condition of the patient (n=126; 27.6%), tumour 
volume or localisation (n=232; 50.8%), patient refusal (n=43; 9.4%), or a combination of these 
reasons (n=26; 6.2%).
In the group of 457 patients for whom the primary debulking surgery was cancelled, 165 patients 
underwent interval debulking. The tumour volume or localisation was the main reason for 
notperforming the primary debulking. A total of 902 patients (75.3%) with advanced stage disease re- 
ceived a primary or interval debulking, and this proportion remained stable over the study period. 
Table 2. Results of the staging procedures for patients with epithelial ovarian cancer (n=453).
 
Characteristic
1996–1999 
(n=139)
2000–2004 
(n=190)
2005–2009 
(n=124)
 
P*
Adequate procedure† 32 (23.0) 61 (32.1) 77 (62.1) <.01
Staging procedures
Abdominal hysterectomy
Bilateral salpingo-oophorectomy
Infracolic omentectomy
1 peritoneal biopsy
1 lymph node
10 lymph nodes
133 (95.6)
122 (87.7)
135 (87.8)
87 (62.6)
51 (36.7)
45 (32.4)
175 (92.1)
170 (89.4)
187 (98.4)
122 (64.2)
88 (46.3)
66 (34.7)
118 (95.2)
119 (96.0)
123 (99.2)
101 (81.5)
98 (79.0)
59 (47.6)
.36
.63
.11
<.01
<.01
<.01
Surgeon attending
Gynaecologic oncologist 51 (36.7) 104 (54.7) 100 (80.6) <.01
Data are n (%) unless otherwise specified.
* χ2 test.
† Adequate procedure defined as including omentectomy, bilateral salpingo-oophorectomy, at least one 
biopsy, and one lymph node.
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The proportion of primary debulking surgeries decreased and the proportion of interval debulking 
surgeries increased (Table 3). The proportions of optimal and complete debulking increased. The 
debulking surgeries were increasingly performed by a gynaecologic oncologist. The location of 
the interval debulking changed significantly over the years.
Figure 1 shows the Kaplan-Meier curves of the progression-free and overall survival in the patient 
groups with diagnoses before and after the collaboration. Survival was not significantly different 
during the two periods, and survival did not improve significantly for patients who underwent 
debulking surgery (Fig. 2). Table 4 shows the variables that independently influence overall 
survival. Younger age, early stage, endometrioid or mucinous histology, lower tumour grade, no 
residual tumour or residual tumour smaller than 1 cm, attendance of a gynaecologic oncologist, 
and adequate chemotherapy were associated with prolonged survival. The type of hospital was 
not associated with survival outcome. Using multivariable Cox regression, we determined the 
following six independent variables: age; stage; tumour grade; completeness of debulking; 
presence of a gynaecologic oncologist; and adequacy of chemotherapy.
Table 3. Debulking procedures for patients with advanced stage epithelial ovarian cancer.
 
Characteristic
1996–1999 
(n=337)
2000–2004 
(n=425)
2005–2009 
(n=435)
 
P*
Primary debulking
Cancelled primary debulking
Interval debulking
Patients undergoing primary or 
interval debulking
Optimal (less than1 cm) debulking
Complete debulking
Gynaecologic oncologist at primary 
debulking
Gynaecologic oncologist at interval 
debulking
230 (68.2)
93 (30.7)
37 (11.0)
251 (74.5) 
143 (57.4)
60 (24.1)
73/230 (31.7) 
24/37 (64.9)
280 (65.9)
138 (32.6)
75 (17.6)
320 (75.3) 
215 (68.0)
118 (37.3)
176/280 (62.9) 
50/75 (66.7)
227 (52.2)
198 (45.9)
144 (33.1)
328 (75.4) 
244 (76.5)
139 (43.4)
186/227 (81.9) 
129/144 (86.9)
<.01
<.01
<.01
.62 
<.01
<.01
<.01 
.001
Hospital of debulking
University
Teaching
Nonteaching
33 (9.8)
122 (36.1)
143 (42.3)
57 (13.4)
151 (35.5)
150 (41.9)
96 (22.1)
129 (29.7)
126 (29.0)
<.01
Data are n (%) unless otherwise specified.
* χ2 test.
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Figure 1. Kaplan-Meier estimates of progression-free survival (A) and overall survival (B) of all 550 patients 
with epithelial ovarian cancer diagnosed between 1996 and 2000 and of the 560 patients with epithelial 
ovarian cancer diagnosed between 2001 and 2005. Vertical bars indicate patients with censored data (alive 
at the last follow-up date). The log-rank test showed no significant difference in progression-free survival 
(P=.26) or in overall survival (P=.23).
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Figure 2. Kaplan-Meier estimates of progression-free survival (A) and overall survival (B) of 441 patients 
undergoing debulking surgery with epithelial ovarian cancer diagnosed between 1996 and 2000 and of 460 
patients with epithe lial ovarian cancer diag nosed between 2001 and 2005. Vertical bars indicate patients 
with censored data (alive at the last follow-up date). The log-rank test showed no significant difference in 
progression-free survival (P=.11) or in overall survival (P=.09).
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Table 4. Overall survival by clinicopathologic variables of patients with epithelial ovarian cancer diagnosed 
between 1996 and 2005.
Clinical variable Crude HR 95% CI Adjusted HR 95% CI
Study period
1996–2000
2001–2005
1.00
0.92
Reference
0.80-1.06
NA
FIGO stage
I
II
III
IV
1.00
2.15
5.74
8.60
Reference
1.51-3.07
4.52-7.30
6.32-11.69
1.00
2.36
4.16
5.71
1.61–3.46
3.00–5.76
3.76–8.66
Histology
Serous
Mucinous
Endometrioid
Adenocarcinoma NOS
Other
1.00
0.49
0.50
1.45
0.73
Reference
0.35-0.67
0.39-0.63
1.22-1.72
0.57-0.95
NA
Grade
I
II
III
1.00
2.73
3.74
Reference
1.98-3.76
2.76-5.05
1.00
1.94
1.90
1.35–2.79
1.34–2.70
Age (y)
Younger than 40
41–59
60–74
Older than 75
1.00
1.46
2.06
5.36
Reference
1.06-2.01
1.51-2.81
3.88-7.40
1.00
0.96
1.19
2.13
0.69–1.35
0.85–1.66
1.47–3.10
Optimal debulking
Yes
No
1.00
3.29
Reference
2.70-4.01
NA
Complete debulking
Yes
No
1.00
3.39
Reference
2.84-4.04
1.00
1.60 1.26–2.04
Chemotherapy
Yes
No
1.00
1.56
Reference
1.36-1.79
1.00
1.81 1.44–2.28
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Clinical variable Crude HR 95% CI Adjusted HR 95% CI
Gynaecologic oncologist at debulking
No
Yes
1.00
0.81
Reference
0.69-0.94
1.00
0.78 0.66–0.93
Hospital volume
Fewer than 20 surgeries per year
More than 20 surgeries per year
1.00
0.91
Reference
0.78-1.06
NA
HR, hazard ratio; CI, confidence interval; NA, not applicable; FIGO, International Federation of Gynecology 
and Obstetrics; NOS, not otherwise specified.
DISCUSSION
This study describes all changes occurring after the regional collaboration for epithelial ovarian 
cancer started in the Netherlands. One prominent change was the increase in surgeries 
performed by gynaecologic oncologists. Introducing the RMI in risk assessment may have 
contributed to this change. Both the staging and debulking results improved greatly during 
the collaboration. Several care changes after the collaboration started may have improved the 
surgery. These changes include multidisciplinary consultation before treatment, using the RMI, 
having gynaecologic oncologists attend the surgeries, the organisation of care for the patients, 
and the protocols and guidelines that are being used in the network. Unfortunately, we can-
not determine the precise reason for the improvements because of the retrospective design of 
the study.
Gynaecologic oncologists attended the staging surgeries of more than 85% of the patients with 
an RMI more than 200. Most of the remaining 15% were treated in one hospital where the semi-
specialising gynaecologist operated with a specialising general surgeon. One might question 
the use of the RMI, which may increase the number of surgeries performed by gynaecologic 
oncologists for benign tumours. However, van den Akker et al.12 show that the opposite is true. 
Moreover, a recent study shows that using the RMI to centralise care is cost-effective.15
While discussing the adequacy of the staging procedure, we found that more than 70% of the 
study population did not undergo optimal staging according to the definition of the Dutch 
evidence-based guideline for epithelial ovarian cancer, which includes at least 10 lymph nodes. 
The benefit of a staging procedure including 10 lymph nodes has never been proven with respect 
to survival, but we know that patients with early stage disease with a well-differentiated tumour 
can be spared chemotherapy.16-18 The role of biopsies of normal peritoneum is still being debated. 
Table 4. Continued
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We chose to present the procedures in the Dutch guideline, which are compatible with the 
quality indicators defined by the European Organisation for Research and Treatment of Cancer–
Gynaecological Cancer Group.19
In a minority of cases, the surgeon outlined the reason for inadequate staging and the majority of 
reasons were valid. We advocate further research to identify factors that affect compliance with 
the guideline in daily practice.
In contrast to the circumstances of the staging procedure, the gynaecologists were aware of the 
inadequate procedure for debulking surgery. The reasons for not achieving complete debulking 
were recorded for most of the patients. Tumour volume and localisation were the main reasons; 
these are well-known factors negatively influencing debulking.20,21
The increase in interval debulking surgeries may have contributed to more complete debulking. 
Studies of interval debulking surgery and survival are contradictory22,23 because of confounding by 
indication. We have no data regarding operative morbidity, which might have added interesting 
information about the differences between primary and interval debulking surgery.
Approximately 25% of all patients with advanced stage disease had no debulking surgery, and this 
proportion was stable over time. This is consistent with data for the whole Dutch population.24 
Apparently, a subgroup of patients is ineligible for surgery mainly because of the volume or 
localisation of the tumour or patient characteristics such as age and comorbidity.
Despite the improvement in clinical care, survival did not improve. There was a nonsignificant 
difference in overall 5-year survival of 3% (from 36% to 39%). An improvement of 3% overall 
survival would be compatible with the Dutch nationwide figures for survival,24 in which 5-year 
relative survival has improved (35% in 1989–1993 compared with 41% in 2004–2009). The lack 
of a significant difference between groups could be attributable to inadequate study size. A post 
hoc power analysis determined that at least 3,045 patients per study group would be necessary to 
show a significant increase of 3% in 5-year survival, based on our observed survival.
The lack of an increase in survival also may be attributed to other factors like the inappropriate 
chemotherapy treatment. Chemotherapy was inadequate for approximately 30% of the patients. 
Chemotherapy was not started for 25% of these patients because of their poor clinical condition. 
The remaining patients, especially during the first study period, never received a platin-containing 
chemotherapeutic or they never received the adequate number of courses, mainly because of 
their condition.
Other factors are the increasing number of high-grade tumours in the second study period, and 
tumour grade is associated with survival in the Cox regression analysis. The increased percentage 
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of serous carcinomas and fewer adenocarcinomas not otherwise specified are probably caused 
by improved diagnostics and therefore are not considered a real shift.
This population-based study covered 14 years and all surgical aspects of ovarian cancer care, 
including reasons for omitting procedures. Although there is enough knowledge about adequate 
surgical procedures, many patients worldwide do not receive the best treatment, partly because 
of lack of collaboration between institutions and physicians. The results of this study look 
promising for future collaboration in the field of gynaecologic oncology. Regional networks can 
help in several ways to enhance management.
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Several methods of preoperative evaluation of ovarian tumours have been reported in litera-
ture. These include imaging techniques such as transvaginal and transabdominal ultrasound, 
computed tomography (CT) scanning, magnetic resonance imaging (MRI), three-dimensional 
ultrasound, and colour Doppler. Furthermore, tumour markers such as cancer antigen 125 
(CA 125) and human epididymis protein 4 (HE4), as well as proteomic techniques are studied. 
In addition, with advances in technology over the years, genetic materials are investigated for 
their use as tumour markers. Epigenetic mechanisms including DNA methylation are extensively 
studied1,2 and could be useful in diagnosing ovarian cancer.
On the basis of several of these techniques, at least 20 prediction models for the ovarian cancer 
risk estimation have been developed and externally validated. The Risk of Malignancy Index 
(RMI)3 was the first prediction model suitable for use in clinical practice. Four versions of the RMI 
have been developed and the first three versions were validated retrospectively and prospectively 
in a variety of clinical studies.
Preoperative assessment is of interest to patient counselling, as well as to the choice of the optimal 
surgical route, but it often requires intraoperative confirmation in order to prevent inadequate 
surgical management (under- and overtreatment). Frozen section analysis is generally accepted 
as a reliable intraoperative diagnostic tool, and is widely used in the intraoperative evaluation of 
ovarian tumours.4-6
The studies in this thesis focused on the RMI, frozen section analysis, and standardised 
laparoscopic examination as preoperative and intraoperative diagnostic tools to discriminate 
between benign ovarian tumours, borderline ovarian tumours (ovarian cancers of low malignant 
potential), and ovarian cancer.
ULTRASOUND MODELS IN THE PREOPERATIVE EVALUATION 
OF OVARIAN TUMOURS
Subjective impression of an experienced ultrasound examiner is currently believed to be the 
best approach to assess an ovarian tumour and no other method or model has proved superior.7 
Several papers have been published addressing the reproducibility of gynaecological ultra-
sound. Basically they all reached the same conclusion: subjective examiner impression is repro-
ducible among expert examiners but not among nonexpert examiners or trainees.8,9 The term 
‘expert examiner’ was variously described as: gynaecologist or radiologist with expertise in 
gynaecological ultrasound and a special interest in adnexal pathology;7 examiner who had more 
than 10 years of experience in gynaecological ultrasound;10,11 examiner with more than 15 years of 
experience;8 senior clinician who had performed at least 5,000 ultrasound scans;9 and examiner 
who had performed over 10,000 gynaecological ultrasound examinations.12
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Most women do not have (easy) access to expert ultrasonographers yet.  Prediction models may 
help less experienced ultrasonographers. The RMI is a popular tool because of its simplicity: little 
experience in ultrasound diagnosis is required to identify the ultrasound features that have to 
be scored (namely: presence of multilocular lesions, solid areas, bilaterality, ascites, and intra-
abdominal metastases), and the algorithm can be calculated easily. The study described in 
Chapter 2 validated the RMI and found sensitivity and specificity levels above 80% for discri-
mination between benign and malignant ovarian tumours with a cut-off level of 200. 
Several other diagnostic models have been developed since the introduction of the RMI, and 
some perform better.13 Recent studies suggested the International Ovarian Tumour Analysis 
(IOTA) Simple Rules (SR)14 as the approach of choice when expert ultrasound expertise is not 
available. The SR are easy to apply, but are applicable (i.e. give a conclusive result) in only 77% 
of ovarian tumours15 and do not provide risk estimates. In case the SR are inconclusive, expert 
ultrasound assessment is indicated. 
The Logistic Regression model LR2 from IOTA is useful to skilled ultrasonographers only, as the 
model requires strict compliance with the ultrasound techniques, terms, and definitions set out 
by the IOTA team.16 Both the SR and LR2 were published after the introduction of our study 
protocol on the external validation of the RMI and were therefore not included in this thesis. They 
are very promising, yet more difficult in their use. These IOTA models should be included in any 
future evaluation of ovarian tumour prediction models. 
The IOTA models have not yet been implemented in the Netherlands. Currently, a prospective 
multicenter Dutch cohort study is being conducted on the performance and cost-effectiveness 
of the SR, followed by subjective assessment or MRI when needed, compared to the RMI 
(SUBSONiC-study).17 The results of this study have to be awaited, but they may have major 
consequences for current Dutch guidelines for women with adnexal masses.
The recently developed Assessment of Different NEoplasias in the adneXa (ADNEX) model18, 
also by IOTA, seems a promising new triage tool for women with ovarian masses. It is the first 
predictive multiclass model able to differentiate between four subgroups of malignant tumours 
(borderline, early stage, advanced stage, and metastatic ovarian cancer). The area under 
the receiver operating characteristic curve (AUC) for the discrimination between benign and 
malignant tumours was 0.94 (95% confidence interval 0.93 to 0.95) on temporal validation. The 
AUC was 0.85 for benign versus borderline, 0.92 for benign versus FIGO stage I cancer, 0.99 for 
benign versus FIGO stage II-IV cancer, and 0.95 for benign versus secondary metastatic cancer, 
respectively. AUCs between malignant subtypes varied between 0.71 and 0.95.
Future studies should focus on external evaluation of the ADNEX model to make sure it performs 
well in various populations, and eventually to evaluate whether incorporating the new model in 
clinical practice actually improves outcomes for women.
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TUMOUR SIZE AND THE EVALUATION OF OVARIAN TUMOURS
The RMI-4,19 validated in a study described in Chapter 3, includes the variable ‘tumour size’. 
Although tumour size is recognised as an independent predictor of malignancy, the additional 
effect on overall model performance may be small, or insignificant. This is illustrated by the LR2 
model, which is a simpler alternative to the LR1.20 The LR1 was the first logistic regression model 
the IOTA group developed, and included tumour size (maximum diameter of three measurements 
of the largest diameters of the lesion in two perpendicular planes) as an independent predictor. 
The LR2 omitted tumour size, and demonstrated similar performance on external validation.
Tumour size plays a role in the accuracy of frozen section analysis: in adnexal masses larger than 
10 cm, a benign result of the frozen section diagnosis is less reliable compared to paraffin section 
evaluation.21 This is caused by the nature of the procedure: there is inadequate time to take many 
slices during frozen section procedure and large tumours may require multiple slices. In paraffin 
section evaluation, the need for multiple slices of large tumours is clearly acknowledged, as it is 
advised by the Dutch national guideline for epithelial ovarian carcinoma to take at least one slice 
per cm diameter, in respect of the diversity of histological components that ovarian tumours may 
contain.22 
MENOPAUSAL STATUS AND THE EVALUATION OF OVARIAN 
TUMOURS
The risk of ovarian cancer is significantly higher in postmenopausal than in premenopausal 
women. The first publication on the RMI3 identified postmenopausal status as an independent 
risk factor for malignancy, and included it as a parameter in the index.
Neither the LR1 and LR2, nor the ADNEX model, included menopausal status but only used 
age. LR1 and LR2 included age, as stepwise multivariate regression analysis revealed age as an 
independent risk factor for the presence of malignancy (a 3.3% increase of odds for malignancy 
with each additional year of age).
In our study cohort, sensitivity and positive predictive value of the RMI (at a cut-off level of 200) 
were lower in premenopausal women (55% and 29%, respectively) than in postmenopausal 
women (90% and 56%, respectively). Based on our results described in Chapter 5, we suggest an 
RMI cut-off of 100 in postmenopausal women to indicate frozen section analysis, whereas a cut-
off of 200 is advised in premenopausal women. This implicates that postmenopausal women with 
an RMI score over 100 should be referred to centre hospitals with the proper expertise available 
to perform a staging procedure if necessary after frozen section analysis. Further prospective 
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research is recommended to determine whether the RMI cut-off level of 100 is to be implemented 
in the clinical management of postmenopausal women with ovarian tumours.
LAPAROSCOPIC EVALUATION OF OVARIAN TUMOURS
Over the last decades, the use of laparoscopy in adnexal mass surgery has increased. One 
concern, however, is the possibility of encountering an unsuspected ovarian malignancy at the 
time of surgery, given that there is no way to preoperatively identify malignant adnexal masses 
with 100% sensitivity and specificity. Laparoscopic surgery is associated with a higher risk of 
intraoperative cyst rupture, which upstages an unexpected ovarian cancer to International 
Federation of Gynecology and Obstetrics (FIGO) stage IC, with the consequences of possible 
need for adjuvant chemotherapy, and a worse prognosis. Furthermore, there is a risk of port-site 
metastases after laparoscopic procedures, although some authors state that this is a surrogate 
for advanced disease and should not be used as an argument against laparoscopic surgery.23,24 
The potential adverse events of laparoscopic surgery in ovarian malignancies appear to be rare, 
and Muzii et al.25 estimated (based on pooled data from laparoscopic case series in literature) a 
rate of unexpected ovarian cancer of 1% in the general population of patients with ovarian cysts 
and masses approached by laparoscopy. In postmenopausal patients the rate of (unexpected) 
ovarian cancer rises to 3%. In masses that demonstrate suspicious features during preoperative 
ultrasound, the rate of ovarian cancer rises further to 13%. This illustrates the need for careful 
patient selection: postmenopausal patients whose preoperative ultrasounds show suspicious 
features may not be the most suitable candidates for laparoscopic removal of an ovarian mass.
It has not been determined whether a standardised laparoscopic examination of an ovarian 
tumour contributes to diagnosing the tumour type, compared with the surgeon’s overall im-
pression based on physical examination, preoperative imaging modalities, and tumour markers. 
Implementation of a standardised system may improve the quality level of laparoscopic 
examination of ovarian tumours, and ultimately may decrease the risk of spilling the contents 
of a malignant mass. Our study in Chapter 6 showed only fair to moderate agreement on the 
diagnosis of malignancy. Overall sensitivity of diagnosis of malignancy was 49% in observers 
deprived of clinical information, with a specificity of 95%. Once clinical information was provided 
the sensitivity and specificity were 61% and 94%, respectively. 
Presence of adhesions seemed to be an independent predictor of ovarian cancer in Chapter 4, but 
although the interobserver agreement for presence of adhesions was good (κ=0.71) for observers 
deprived of clinical information, adhesions were not only observed in malignant cases (38%) but 
also in benign cases (44%), endometriosis in particular. Once clinical information was provided, 
interobserver agreement for presence of adhesions was moderate (κ=0.52), and adhesions were 
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observed in 27% of malignant and 40% of benign cases. Our results of laparoscopic assessment 
of ovarian tumours may be brought on by the study method: the use of video recordings may 
not reflect conditions during standard laparoscopic examination by the observers, resulting in 
inaccuracies in the assessment of diagnostic features. Furthermore, in our study the number of 
malignant and borderline cases was too low with respect to benign cases. 
Future studies on laparoscopic observation of ovarian tumours need to focus on live laparoscopic 
images including consecutive patients for a representative sample of study patients.
ALLOCATION OF BORDERLINE TUMOURS IN STUDIES 
INVOLVING OVARIAN TUMOURS
To allocate borderline tumours to either benign or malignant is debatable in any study involving 
ovarian tumours. We allocated borderline tumours to the benign group in Chapters 2, 3, 4 and 
5 because the primary goal for developing the RMI was the distinction between malignant and 
borderline and benign cysts. The objective was the referral of patients with ovarian cancer to 
gynaecologic oncologists for appropriate surgical staging and possible tumour debulking 
surgery. The value of staging in borderline tumours is debatable, and it is generally accepted 
that omitting a staging procedure in such cases is unlikely to have a significant adverse effect on 
subsequent clinical management or prognosis.26,27 In case borderline tumours were allocated to 
the malignant group, the test characteristics of the RMI would have changed, most importantly 
the sensitivity would lower from 81% to 62%. 
When evaluating ovarian tumours intraoperatively (Chapter 6), we decided to group the 
borderline tumours with malignant tumours, given the high conversion rate from borderline to 
malignant on the final histology report.28 In case borderline tumours were allocated to the benign 
group, overall sensitivity of diagnosis of malignancy in observers deprived of clinical information 
would rise from 49% to 70%; in observers provided with clinical information the sensitivity would 
rise from 61% to 77%. 
CENTRALISATION OF CARE FOR OVARIAN CANCER PATIENTS
The treatment of ovarian cancer is now formally centralised in the Netherlands and only three 
of the 11 hospitals included in our studies still perform ovarian cancer surgery. The operations on 
patients with suspicion of malignancy are always performed by gynaecologic oncologists (centre 
hospital) or attended by gynaecologic oncologists (teaching hospitals).
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CONCLUSIONS AND IMPLICATIONS
An accurate preoperative evaluation is essential to make sure that ovarian cancer patients are 
treated in high-volume institutions to ensure the best prognosis and survival chances. Prior 
knowledge of the nature of an ovarian mass is not only essential to the patient but also to the 
clinic in organising planning, costs, and overall management. Subjective impression by an 
experienced ultrasound examiner seems the best approach. When expert ultrasonographers are 
not available, the RMI can be used to predict the risk of malignancy. An RMI cut-off value of 200 
is advised in premenopausal women to indicate frozen section analysis, whereas a cut-off of 100 
is suggested in postmenopausal women. In the likelihood of a (borderline) ovarian malignancy, 
patients should be treated in centres with access to frozen section analysis and gynaecologic 
oncologists. The treatment of ovarian cancer is now formally centralised in the Netherlands. 
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Chapter 9
SUMMARY
This thesis contains studies that evaluate opportunities to improve the preoperative and 
intraoperative diagnosis of ovarian tumours. As described in Chapter 1, the discriminative 
preoperative evaluation of ovarian tumours is rather difficult, as most ovarian masses are not 
immediately classifiable. The presumed diagnosis based on preoperative evaluation will guide 
the decision-making on the surgical approach. Treatment of benign ovarian tumours differs 
greatly from treatment of malignant tumours and the prognosis of women with ovarian cancer 
is influenced by appropriate surgery by a gynaecologic oncologist. An accurate preoperative 
diagnosis in women with ovarian tumours is therefore essential, not only to the patient but also 
to the clinic in organising planning, costs, and overall management. 
Several diagnostic procedures are available for the assessment of ovarian tumours, and various 
prediction models for ovarian cancer risk estimation have been developed over time. The Risk 
of Malignancy Index (RMI) was the first diagnostic model for ovarian cancer risk estimation 
suitable for use in clinical practice. Four versions of the RMI have been developed and the first 
three versions were validated retrospectively and prospectively in a variety of clinical studies. 
Chapter 2 describes a study that evaluated the RMI-3. We performed a prospective observational 
multicentre study in the eastern part of the Netherlands that included 548 women with ovarian 
tumours. All the patients included were preoperatively evaluated without applying the RMI. The 
RMI was calculated afterwards by using registered data, to hypothesise how the management 
would have been changed (regarding referral of patients to gynaecologic oncologists in specialised 
centres) if the RMI was used to discriminate patients with low and high risk for malignancy. The 
results showed an increase of ovarian cancer patients operated by gynaecologic oncologists from 
64% in current practice to 80% if the RMI would have been applied with the cut-off level of 200.
Adding tumour size as an additional parameter to the model does not improve the performance 
of the RMI, as shown in Chapter 3. Our study validated the RMI-4 by applying the index to a 
new study population and comparing its performance with the RMI-3. The models demonstrated 
similar performances. We found lower sensitivity and specificity levels compared to the original 
report on RMI-4. This is a common finding of external validation of proposed models and illustrates 
the need for external validation of any prediction model before introducing into clinical practice.
Preoperative assessment is of interest to patient counselling, as well as to the choice of the 
optimal surgical route, but it often requires intraoperative confirmation in order to prevent 
inadequate surgical management (under- and overtreatment). Frozen section analysis is widely 
used in the intraoperative evaluation of ovarian tumours and is generally accepted as a reliable 
method. Various factors influence the surgeon’s use of frozen section analysis, depending on the 
suspicion of malignancy. The study described in Chapter 4 investigated factors relating to the 
use of frozen section analysis in ovarian tumours. We conducted a retrospective cohort study and 
included 670 patients who underwent surgery for an ovarian tumour. We concluded that frozen 
121
Summary | Samenvatting
9
section analysis is useful when the serum tumour marker cancer antigen 125 (CA 125) levels are 
greater than 35 units/mL and when there are multilocular tumours and solid areas visible on 
ultrasonography, and adhesions revealed during surgery. 
Our study described in Chapter 5, evaluated the use of the RMI to indicate frozen section analysis 
in women with ovarian tumours. We concluded that women with an RMI below 20 do not need 
frozen section analysis, as their risk of malignancy is very low. Furthermore, we suggested an RMI 
cut-off of 100 in postmenopausal women to indicate frozen section analysis, whereas a cut-off of 
200 is advised in premenopausal women. This implicates that postmenopausal women with an 
RMI score of over 100 should be referred to centre hospitals with the proper expertise available 
to perform a staging procedure if necessary after frozen section analysis.
Laparoscopy is a common approach as a diagnostic tool and for the surgical removal of 
(presumably benign) ovarian tumours. It has not been determined whether a standardised 
laparoscopic examination of an ovarian tumour contributes to diagnosing the tumour type, 
compared with the surgeon’s overall impression based on physical examination, preoperative 
imaging modalities, and tumour markers. As a first step to investigate this subject, our study 
in Chapter 6 evaluated diagnostic performances of evaluations of 41 videotaped laparoscopic 
examinations of ovarian tumours. The study showed only fair to moderate agreement on the 
diagnosis of malignancy. Overall sensitivity of diagnosis of malignancy was 49% in observers 
deprived of clinical information, and 61% in observers provided with clinical information. 
Chapter 7 describes a retrospective population-based study on 1554 ovarian cancer patients in 
the eastern part of the Netherlands. This chapter gives an overview of all the changes that took 
place after starting a regional collaboration among ovarian cancer patients. The most prominent 
changes were that more surgeries were performed by gynaecologic oncologists. The regional 
introduction of the use of the RMI in risk assessment may have contributed to this change. Both 
the staging and debulking surgery results have greatly improved with the collaboration. A trend 
towards an improvement in survival could be seen over the period from 1996 till 2005. 
In Chapter 8 we discuss the outcomes of the studies described in this thesis. Subjective impres-
sion by an experienced ultrasound examiner seems to be the best approach to assess an ovarian 
tumour. When expert ultrasonographers are not available, the RMI can be used to predict the risk 
of malignancy. In the likelihood of a (borderline) ovarian malignancy, patients should be treated 
in centres with access to frozen section analysis and gynaecologic oncologists. The treatment of 
ovarian cancer is now formally centralised in the Netherlands.
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SAMENVATTING
Dit proefschrift bevat studies naar het verbeteren van de pre-operatieve en intra-operatieve 
diagnostiek van eierstoktumoren. Zoals beschreven in Hoofdstuk 1 komen eierstoktumoren 
veelvuldig voor in de dagelijkse gynaecologische praktijk. Vaak is het lastig om pre-operatief een 
correct onderscheid te maken tussen een goedaardige eierstoktumor of eierstokkanker, omdat 
de meeste tumoren niet direct te classificeren zijn. Wanneer het vermoeden bestaat dat er sprake 
is van eierstokkanker, is verwijzing naar een oncologisch centrumziekenhuis noodzakelijk. Hier 
werken gynaecologisch oncologen die zijn gespecialiseerd in de vaak complexe operaties die 
nodig zijn om zoveel mogelijk tumorweefsel te verwijderen. Wetenschappelijk onderzoek heeft 
aangetoond dat wanneer de zorg voor patiënten met eierstokkanker wordt gecentraliseerd dit 
een gunstige uitwerking heeft op de lange termijn prognose en overlevingskans.
Er zijn verscheidene diagnostische middelen beschikbaar om eierstoktumoren te evalueren 
en in de loop der jaren zijn talrijke predictiemodellen ontwikkeld voor het voorspellen van de 
kans op kwaadaardigheid. De Risk of Malignancy Index (RMI) is het eerste predictiemodel dat 
geschikt was voor gebruik in de klinische praktijk. Er zijn vier versies van de RMI ontwikkeld en de 
eerste drie versies zijn veelvuldig onderzocht in diverse klinische studies. Hoofdstuk 2 beschrijft 
een studie waarin we de RMI-3 evalueerden. We voerden een prospectieve observationele 
multicenterstudie uit in het oostelijk deel van Nederland en includeerden 548 vrouwen met 
eierstoktumoren. Alle geïncludeerde patiënten zijn pre-operatief onderzocht met de standaard 
diagnostische middelen, zónder het toepassen van de RMI. De RMI berekenden we achteraf 
zodat we konden beredeneren hoe de behandeling zou zijn geweest (wel of niet verwezen naar 
een gynaecologisch oncoloog) als de RMI zou zijn gebruikt om onderscheid te maken tussen 
patiënten met een lage en hoge kans op kwaadaardigheid. De resultaten van onze studie laten 
zien dat het percentage patiënten met eierstokkanker dat geopereerd zou worden door een 
gynaecologisch oncoloog zou stijgen van 64% in de huidige situatie naar 80% als de RMI zou zijn 
gebruikt (met een afkapwaarde van 200).
Het toevoegen van tumorgrootte als extra variabele leidt niet tot een verbeterde prestatie van 
de RMI, zoals Hoofdstuk 3 laat zien. De studie die in dit hoofdstuk wordt beschreven, valideerde 
de RMI-4 door deze toe te passen op een nieuwe studiepopulatie en de testeigenschappen te 
vergelijken met de RMI-3. De modellen laten overeenkomstige resultaten zien. We vonden een 
lagere sensitiviteit en specificiteit dan in de originele rapportage over de RMI-4. Dit is een veel 
voorkomende bevinding van een externe validatie en geeft het belang aan van externe validatie 
van een predictiemodel voordat deze wordt toegepast in de klinische praktijk.
Pre-operatieve diagnostiek is van belang voor het adviseren van de patiënt en voor de keuze 
van de operatieve benadering. Vaak is intra-operatieve bevestiging nodig om een suboptimale 
operatieve behandeling te voorkomen (onder- en overbehandeling). Vriescoupe-diagnostiek is 
algemeen geaccepteerd als een betrouwbare intra-operatieve diagnostische methode en wordt 
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veelvuldig gebruikt in de intra-operatieve beoordeling van eierstoktumoren. Verschillende 
factoren hebben invloed op de beslissing van de operateur om vriescoupe-diagnostiek in te 
zetten, afhankelijk van de verdenking op kwaadaardigheid. De studie beschreven in Hoofdstuk 
4 onderzocht factoren die verband houden met de inzet van vriescoupe-diagnostiek bij 
eierstoktumoren. We voerden een retrospectieve cohortstudie uit en includeerden 670 patiënten 
die een ingreep ondergingen aan een eierstoktumor. We concludeerden dat vriescoupe-
diagnostiek nuttig is bij een waarde van tumormerkstof CA 125 hoger dan 35 eenheden/ml, als 
er multiloculaire tumoren of solide partijen worden gezien bij echoscopisch onderzoek en indien 
verklevingen worden gezien tijdens de operatieve ingreep.
Onze studie beschreven in Hoofdstuk 5 evalueerde het gebruik van de RMI in de beslissing om 
vriescoupe-diagnostiek te verrichten bij vrouwen met eierstoktumoren. We concludeerden dat 
bij vrouwen met een RMI lager dan 20 geen vriescoupe-diagnostiek nodig is, aangezien de kans 
op kwaadaardigheid in deze groep erg laag is. Verder suggereerden we een RMI-afkapwaarde 
van 100 in post-menopauzale vrouwen om vriescoupe-diagnostiek uit te voeren, terwijl een 
afkapwaarde van 200 van toepassing is bij pre-menopauzale vrouwen. Dit houdt in dat post-
menopauzale vrouwen met een RMI van 100 of hoger verwezen zouden moeten worden naar een 
oncologisch centrum dat over de expertise beschikt om een stadiëringsprocedure uit te voeren.
Laparoscopie is een algemeen gebruikte techniek voor het operatief verwijderen van (vermoe-
delijk goedaardige) eierstoktumoren en dient tevens als diagnostisch middel om onnodige 
buikoperaties bij patiënten met goedaardige tumoren te voorkomen. Het is nog onduidelijk of 
een gestandaardiseerde laparoscopische benadering van een eierstoktumor bijdraagt aan het 
diagnosticeren van het tumortype, in vergelijking met de klinische inschatting van de chirurg 
gebaseerd op lichamelijk onderzoek, preoperatieve beeldvorming en tumormerkstoffen. Als 
eerste stap om dit te onderzoeken, evalueerde onze studie in Hoofdstuk 6 de diagnostische 
waarde van evaluaties van 41 video-opnames van laparoscopische verrichtingen bij eier-
stoktumoren. De overeenkomst tussen de beoordelingen betreffende de diagnose van kwaad-
aardigheid was matig tot redelijk. De sensitiviteit van diagnose van een kwaadaardigheid was 
49% bij beoordelaars geblindeerd voor klinische informatie en 61% bij beoordelaars die klinische 
informatie tot hun beschikking hadden.
Hoofdstuk 7 beschrijft een retrospectief population-based onderzoek bij 1554 patiënten met 
eierstokkanker in het oostelijk deel van Nederland. Dit hoofdstuk geeft een overzicht van 
alle veranderingen die plaatsvonden na de start van een regionale samenwerking rondom de 
zorg voor patiënten met eierstokkanker. De voornaamste verandering was dat meer operaties 
werden uitgevoerd door gynaecologisch oncologen. De regionale introductie van de RMI heeft 
hier mogelijk een rol bij gespeeld. Zowel de stadiëring als debulking operatie-uitkomsten zijn 
verbeterd door de samenwerking. Er is een trend te zien richting verbetering van de overleving 
tijdens de periode 1996 tot 2005.
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In Hoofdstuk 8 bespreken we de uitkomsten van de studies die in dit proefschrift staan be-
schreven. De subjectieve beoordeling door een ervaren echoscopist lijkt de beste manier om 
een eierstoktumor te evalueren. Indien ervaren echoscopisten niet beschikbaar zijn, kan de RMI 
worden toegepast om de kans op kwaadaardigheid te voorspellen. Indien er waarschijnlijk sprake 
is van een (borderline) kwaadaardigheid van de eierstok, zouden patiënten behandeld moeten 
worden in centra waar vriescoupe-diagnostiek en gynaecologisch oncologen beschikbaar zijn. 
De behandeling van eierstokkanker is in Nederland tegenwoordig formeel gecentraliseerd. 
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